Naar www.iknl.nl
- Long > Niet kleincellig longcarcinoom
Notificatie richtlijn E-mail richtlijn Naar startpagina oncoline
----------

Laatst gewijzigd : 2015-12-18, Versie: 2.3, Verantwoording: Landelijke Werkgroep Longtumoren, Type: Landelijke richtlijn

Referentielijst

1 - Aupérin A. (2010)
A. Aupérin, C. Le Péchoux, E. Rolland, W.J. Curran, K. Furuse, P. Fournel, J.Belderbos, G. Clamon, H.C. Ulutin, R. Paulus, T. Yamanaka, MC. Bozonnat, L. Uitterhoeve, X.F. Wang, L. Stewart, R. Arriagada, S. Burdett, JP. Pignon, on behalf of the NSCLC Collaborative Group. Concomitant versus sequential radiochemotherapy in locally advanced non-small cell lung cancer: A meta-analysis of individual data of 1205 patiënts. J Clin Oncol 2010, 28(13):2181-90.
 
2 - Aaby C (1995)
Aaby C, Kristensen S, Nielsen SM. Mediastinal staging of non-small-cell lung cancer: computed tomography and cervical mediastinoscopy. J Otorhinolaryngol Relat Spec:57:279-285, 1995.
 
3 - Adams K (2009)
Adams K, Shah PL, Edmonds L, Lim E. Test performance of endobronchial ultrasound and transbronchial needle aspiration biopsy for mediastinal staging in patiënts with lung cancer: systematic review and meta-analysis. Thorax 64:757-762, 2009.
 
4 - Adlard JW (2001)
Adlard JW, Joseph J, Brammer CV, Gerrard GE. Open access follow-up for lung cancer: patiënt and staff satisfaction. Clin Oncol (R Coll Radiol) 13:404-408, 2001.
 
5 - Alatas F (2002)
Alatas F, Alatas O, Metintas M, Colak O, Erginel S, Harmanci E. Usefulness of bone markers for detection of bone metastases in lung cancer patiënts. Clin Biochem 35:293-296, 2002.
 
6 - Albain KS (2009)
Albain KS, Swann RS, Rusch VW, Turrisi AT, III, Shepherd FA, Smith C, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 374:379-386; 2009.
 
7 - Albertucci M (1992)
Albertucci M, Meester T de, Rothberg M, Hagen J, Santoscoy R, Smyrk T. Surgery and the management of peripheral lung tumors adherent to the parietal pleura. J Thorac Cardiovasc Surg 103:8-12, 1992.
 
8 - Alexiou C (2003)
Alexiou C, Beggs D, Onyeaka P, Kotidis K, Ghosh S, Beggs L, et al. Pneumonectomy for Stage I (T1N0 and T2N0) Nonsmall Cell lung Cancer Has Potent, Adverse Impact on Survival. Ann Thorac Surg 76:1023-1028, 2003
 
9 - Alexiou C (2003)
Alexiou C, Beggs D, Onyeaka P, Kotidis K, Ghosh S, Beggs L, et al. Pneumonectomy for Stage I (T1N0 and T2N0) Nonsmall Cell lung Cancer Has Potent, Adverse Impact on Survival. Ann Thorac Surg 76:1023-1028, 2003.
 
10 - Alifano M (2003)
Alifano M, D'Aiuto M, Magdeleinat P, et al. Surgical treatment of superior sulcus tumors: Results and prognostic factors. Chest 124:996-1003, 2003.
 
11 - Allareddy V (2010)
Allareddy V, Ward, MM, Allareddy V, et al. Effect of meeting Leapfrog volume thresholds on complication rates following complex surgical procedures. Annals of Surgery 251, 377-383, 2010.
 
12 - Allen MS (2006)
Allen MS, Darling GE, Pechet TT, Mitchell JD, Herndon JE, Landreneau RJ, et al. Morbidity and mortality of major pulmonary resections in patiënts with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial. Ann Thorac Surg ;81:1013-1019, 2006.
 
13 - Altorki NK (2010)
Altorki NK. Stereotactic body radiation therapy versus wedge resection for medically inoperable stage I lung cancer: tailored therapy or one size fits all? J Clin Oncol 28:905-907, 2010.
 
14 - Alzahouri K (2005)
Alzahouri K, Lejeune C, Woronoff-Lemsi MC, Arveux P, Guillemin F. Cost-effectiveness analysis of strategies introducing FDG-PET into the mediastinal staging of non-small-cell lung cancer from the French healthcare system perspective. Clin Radiol 60:479-492, 2005.
 
15 - Angeletti CA (1995)
Angeletti CA, Mussi A, Janni A, Lucchi M, Ribechini A, Chella A, et al. Second primary lung cancer and relapse: treatment and follow-up. Eur J Cardiothorac Surg 9:607-611, 1995.
 
16 - Annema JT (2009)
Annema JT, Bohoslavsky R, Burgers S, Smits M, Taal B, Venmans B, et al. Implementation of endoscopic ultrasound for lung cancer staging. Gastrointest Endosc 2009 Nov 9.
 
17 - Annema JT (2010)
Annema JT, van Meerbeeck JP, Rintoul RC, Dooms C, Deschepper E, et al Mediastinoscopy vs Endosonography for Mediastinal Nodal Staging of Lung Cancer: A Randomized Trial. JAMA 304:2245-2252, 2010.
 
18 - Annema JT (2005)
Annema JT, Versteegh MI, Veselic M, Voigt P, Rabe KF. Endoscopic ultrasound-guided fine-needle aspiration in the diagnosis and staging of lung cancer and its impact on surgical staging. J Clin Oncol ;23:8357-8361, 2005.
 
19 - Annema JT (2005)
Annema JT, Versteegh MI, Veselic M, Welker L, Mauad T, Sont JK, et al. Endoscopic ultrasound added to mediastinoscopy for preoperative staging of patiënts with lung cancer. JAMA ;294:931-936, 2005.
 
20 - Araki J (2005)
Araki J, Okamoto I, Suto R, Ichikawa Y, Sasaki Ji. Efficacy of the tyrosine kinase inhibitor gefitinib in a patiënt with metastatic small cell lung cancer. Lung Cancer 48:141-144, 2005.
 
21 - Reck M (2010)
Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, Manegold C. Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 21:1804-1809, 2010.
 
22 - Ardizzoni A (2007)
Ardizzoni A, Boni L, Tiseo M, et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patiënt data meta-analysis. J Natl Cancer Inst 99:847-857, 2007.
 
23 - Arriagada JCO (2010)
Arriagada JCO, Dunant A, Pignon JP, Bergman B, Chabowski M, Grunenwald D, Kozlowski M, Le Péchoux C, Pirker R, Pinel MI, Tarayre M, Le Chevalier T. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol. 2010 Jan 1;28(1):35-42.
 
24 - Asamura H (1999)
Asamura H, Nakayama H, Kondo H, Tsuchiya R, Naruke T. Lobe-specific extent of systematic lymph node dissection for non-small cell lung carcinomas according to a retrospective study of metastasis and prognosis. J Thorac Cardiovasc Surg 117:1102-1111 1999.
 
25 - Asamura H (1996)
Asamura H, Nakayama H, Kondo H, Tsuhiya R, Shimosato Y, Naruke T. Lymph node involvement, recurrence, and prognosis in resected small, peripheral, non-small-cell lung carcinomas: are these carcinomas candidates for video-assisted lobectomy? J Thorac Cardiovasc Surg 111:1125-1134, 1996.
 
26 - Asamura H (1992)
Asamura H, Naruke T, Tsuchiya R, Goya T, Kondo H, Suemasu K. Bronchopleural fistulas associated with lung cancer operations. Univariate and multivariate analysis of risk factors, management and outcome. J Thorac Cardiovasc Surg 104:1456-464, 1992.
 
27 - Association of directors of anatomic and surgical pathology (1995)
Association of directors of anatomic and surgical pathology. No authors listed. Association of directors of anatomic and surgical pathology. Recommendations for the reporting of resected primary lung carcinomas. Am J Clin Pathol 269:937-939, 1995.
 
28 - Aupérin A (2006)
Aupérin A, Le Pechoux C, Pignon JP, et al. Concomitant radio-chemotherapy based on platin compounds in patiënts with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patiënts. Ann Oncol 17: 473-483, 2006.
 
29 - Davidoff AJ (2010)
Davidoff AJ, Tang M, Seal B, Edelman MJ. Chemotherapy and survival benefit in elderly patiënts with advanced Non–Small-Cell Lung Cancer. J Clin Oncol 28:2191-2197, 2010.
 
30 - Bach PB (2001)
Bach PB, Cramer LD, Schrag D, Downey RJ, Seand Begg CB. The influence of hospital volume on survival after resection for lung cancer. N Engl J Med 345:181-188, 2001.
 
31 - Baggstrom MQ (2007)
Baggstrom MQ, Stinchcombe TE, Fried DB, et al. Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis. J Thorac Oncol 2007;2:845-853.
 
32 - Ball D (1999)
Ball D, Bishop J, Smith J, O’Brien P. A randomised phase III study of accelerated or standard fraction radiotherapy with or without concomitant carboplatin in inoperable non-small cell lung cancer: final report of an Australian multicentre trial. Radiother Oncol 52:129-136, 1999.
 
33 - Ball D (2009)
Ball D. et al. The complex relationship of lung tumor volume tosurvival in patiënts with non-small cell lung cancer treated with definitive radiotherapy: Trans Tasman Radiation Oncology Group Study 9905. J Thor Oncol S2009.
 
34 - Ball D (2008)
Ball D. Extracranial stereotactic body radiotherapy for stage I non-small cell lung cancer: still investigational or standard of care? J Thorac Oncol 3:1209-1210, 2008.
 
35 - Ball D (2008)
Ball D. Stereotactic radiotherapy for nonsmall cell lung cancer. Current Opinion in Pulmonary Medicine. In Neoplasms of the lung: Edited by Alan M. Fein and David Ost, Curr Opin Pulm Med. 2008 Jul;14(4):297-302.
 
36 - Barlési F (2005)
Barlési F, Pugol J-L. Combination of chemotherapy without platinum compounds in the treatment of advanced non-small cell lung cancer: a systematic review of phase III trials. Lung Cancer 2005;49:289-298.
 
37 - Battafarano R (2002)
Battafarano R, Meyers B, Guthrie T, Cooper J, Patterson A. Surgical resection of multifocal non-small cell lung cancer is associated with prolonged survival. Ann Thorac Surg 74:988-994, 2002.
 
38 - Battafarano RJ (2002)
Battafarano RJ, Piccirillo JF, Meyers BF, Hsu HS, Guthrie TJ, Cooper JD, et al. Impact of comorbidity on survival after surgical resection in patiënts with stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 123:280-287, 2002.
 
39 - Baumann P (2006)
Baumann P, Nyman P, Lax I, Friesland S, Hoyer M, et al. Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patiënts treated in the Nordic countries. Acta Oncologica 45:787-795, 2006.
 
40 - Bechard D (1987)
Bechard D. Assessment of exercise oxygen consumption as preoperative criterion for lung resection. Ann Thorac Surg 44(4):344-349, oct.1987
 
41 - Bechard D (1978)
Bechard D. Assessment of exercise oxygen consumption as preoperative criterion for lung resection. Ann Thorac Surg 44(4):344-9, Oct. 1978
 
42 - Beckles MA (2003)
Beckles MA, Spiro SG, Colice GL, Rudd RM. Initial evaluation of the patiënt with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes. Chest 123:97S-104S, 2003.
 
43 - Begg CB (1998)
Begg CB, Cramer LD, Hoskins WJ, Brennan MF. Impact of hospital volume on operative mortality for major cancer surgery. JAMA 280:1747-1751, 1998.
 
44 - Begg CB (1998)
Begg CB, Cramer LD, Hoskins WJ, Brennan MF. Impact of hospital volume on operative mortality for major cancer surgery. JAMA 280:1747-1751, 1998.
 
45 - Thompson E (2005)
Thompson E. Non-invasive interventions for improving well-being and quality of life in patiënts with lung cancer: A systematic review of the evidence. Lung Cancer 2005, vol 50, 163-176.
 
46 - Belani CP (2005)
Belani CP, Fossella F: Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced non-small cell lung carcinoma (TAX 326). Cancer 104: 2766-2774, 2005.
 
47 - Belderbos J (2007)
Belderbos J, Uitterhoeve L, Zandwijk N van, et al. Randomised trial of sequential versus concomitant chemo-radiotherapy in patiënts with inoperable non-small cell lung cancer (EORTC 08972-22973). Eur J Cancer 43: 114-121, 2007.
 
48 - Benedict S (1994)
Benedict S, Williams RD, Baron PL. Recalled anxiety: from discovery to diagnosis of a benign breast mass. Oncol Nurs Forum 21:1723-1727, 1994.
 
49 - Bernard A (2000)
Bernard A, Ferrand L, Hagry O, Benoit L, Cheynel N, Favre JP. Identification of prognostic factors determining risk groups for lung resection. Ann Thorac Surg ;70:1161-1167, 2000.
 
50 - Biesma B (2011)

Biesma B, Wymenga M, Groen HJM et al. Quality of life, geriatric assessment and survival in elderly patients with non-small-cell lung cancer treated with carboplatin-gemcitabine or carboplatin-paclitaxel: NVALT-3 a phase III study. Ann Oncology 2011; ANNONC-2010-0749.R1.

 
51 - Biesma B (2011)
Biesma B, Wymenga M, Groen HJM et al. Quality of life, geriatric assessment and survival inelderly patients with non-small-cell lung cancer treated with carboplatin-gemcitabine or carboplatin-paclitaxel: NVALT-3 a phase III study. Ann Oncology 2011; ANNONC-2010-0749.R1.
 
52 - Billing JS (1996)
Billing JS, Wells FC. Delays in the diagnosis and surgical treatment of lung cancer. Thorax 51:903-906, 1996.
 
53 - Birdas TJ (2006)
Birdas TJ, Koehler RP, Colonias A, et al. Sublobar resection with brachytherapy versus lobectomy for stage Ib nonsmall cell lung cancer. Ann Thorac Surg 81:434–438, discussion 438-439, 2006.
 
54 - Birkmeyer JD (2002)
Birkmeyer JD, Siewers AE, Finlayson EVA, et al. Hospital volume and surgical mortality in the United States. New Engl J Med 346:1128-1137, 2002.
 
55 - Blanke C (1995)
Blanke C, Ansar R, Mantravadi R, Gonin R. Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small cell lung cancer: a Hoosier Oncology Group protocol. J Clin Oncol 13:1425-1429, 1995.
 
56 - Blasberg J (2010)
Blasberg J, Pass HI, Donington JS. Sublobar resection, a movement from the Lung Cancer Sudy Group. J Thor Oncol 5:10, 1583-1593, 2010.
 
57 - Blauwdruk kanker en werk (2009)
Blauwdruk kanker en werk. http://www.oncoline.nl/kanker-en-werk, 2009
 
58 - Boland GW (1995)
Boland GW, Goldberg MA, Lee MJ, Mayo-Smith WW, Dixon J, McNicholas MM, et al. Indeterminate adrenal mass in patiënts with cancer: Evaluation at PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 194:131-134, 1995.
 
59 - Bollen ECM (1993)
Bollen ECM, Duin CJ van, Theunissen PHMH, Hof-Grootenboer BP van ‘t, Blijham GH. Mediastinal lymph node dissection in resected lung cancer: morbidity and accuracy of staging. Ann Thorac Surg 55:961-966, 1993.
 
60 - Bolliger CT (1995)
Bolliger CT. Exercise capacity as a predictor of postoperative complications in lung resection candidates. Am J Respir Crit Care Med 151:1472-1480, 1995.
 
61 - Bonner JA (1998)
Bonner JA, McGinnis WL, Stella PJ, Marschke R-FJ, Sloan JA, Shaw EG, et al. The possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced nonsmall cell lung carcinoma: results of a North Central Cancer Treatment Group Phase III Study. Cancer 82:1037-1048, 1998.
 
62 - Borne HW van den (1983)
Borne HW van den, Pruyn JFA. Achtergronden en betekenis van lotgenotencontact bij kankerpatienten. Tilburg: IVA, 1983.
 
63 - Borst GR (2009)
Borst GR, Ishikawa M, Nijkamp J, Hauptmann M, Shirato H, Onimaru R, van den Heuvel MM, Belderbos J, Lebesque JV, Sonke JJ. Radiation pneumonitis in patiënts treated for malignant pulmonary lesions with hypofractionated radiation therapy. Radiother Oncol 91:307-313, 2009.
 
64 - Boushy SF (1971)
Boushy SF, Billig DM, North LB, Helgason AH. Clinical course related to preoperative and postoperative pulmonary function in patiënts with bronchogenic carcinoma. Chest 59:383-391, 1971.
 
65 - Boyer MJ (2001)
Boyer MJ, Viney R, Fulham M, King M, McCaughan B, Kenny P, et al. A randomised trial of conventional staging (CS) with or without positron emission tomography (PET) in patiënts (Pts) with stage 1 or 2 non-small cell lung cancer (NSCLC). ASCO , abstract 1233, 2001.
 
66 - Bozcuk H (2001)
Bozcuk H, Martin C. Does treatment delay affect survival in non-small cell lung cancer? A retrospective analysis from a single UK centre. Lung Cancer 34:243-452, 2001.
 
67 - Branston LK (2002)
Branston LK, Greening S, Newcombe RG, Daoud R, Abraham JM, Wood F, et al. Implementation of guidelines and computerized forms improves completeness of cancer pathology reporting. The CROPS project: a randomized controlled trial in pathology. Eur J Cancer 38:764-772, 2002.
 
68 - Bria WF (1983)
Bria WF, Kanarek DJ, Kazemi H. Prediction of postoperative pulmonary function following thoracic operations. Value of ventilation-perfusion scanning. Thorac Cardiovasc Surg 86:186-192, 1983.
 
69 - British Thoracic Society (2001)
British Thoracic Society. Society of Cardiothoracic Surgeons of Great Britain and Ireland Working Party. BTS guidelines: guidelines on the selection of patiënts with lung cancer for surgery. Thorax 56:89-108, 2001.
 
70 - Brodowicz T (2006)
Brodowicz T, Krzakowski M, Zwitter M, et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial. Lung Cancer 52:155-163, 2006.
 
71 - Brunelli A. (2009)
Brunelli A., Charloux A, Bollinger CT, Rocco CT, Sculier JP, Varela G, et al. European Respiratory Society and European Society of Thoracic Surgeons joint task force on fitness for radical therapy. Eur Respir J 34:17-41; 2009.
 
72 - Buhr J (1997)
Buhr J, Berghauser KH, Gonner S, Kelm C, Burkhardt EA, Padberg WM. The prognostic significance of tumor cell detection in intraoperative pleural lavage and lung tissue cultures for patiënts with lung cancer. J Thorac Cardiovasc Surg 113:683-690, 1997.
 
73 - Burt ME (1987)
Burt ME, Pomerantz AH, Bains MS, Mc Cormack PM, Kaiser LR, Hilaris BS, Martini N. Results of surgical treatment of stage III lung cancer invading the mediastinum. Surg Clin North Am 67:987-1000, 1987.
 
74 - Bury T (1998)
Bury T, Barreto A, Daenen F, Barthelemy N, Ghaye B, Rigo P. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patiënts with non-small cell lung cancer. Eur J Nucl Med 25:1244-1247, 1998.
 
75 - Butts (2010)
Butts CA, et al., Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol. 2010 Jan 1;28(1):29-34
 
76 - Byhardt RW (1995)
Byhardt RW. The evolution of Radiation Therapy Oncology Group (RTOG) protocols for nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys 32:1513-1525, 1995.
 
77 - Cappuzzo F (2010)
Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczésna A, Juhász E, Esteban E, Molinier O, Brugger W, Melezínek I, Klingelschmitt G, Klughammer B, Giaccone G., and on behalf of the SATURN investigators. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. The Lancet Oncology 11:521-529; 2010.
 
78 - Cappuzzo F (2007)

Cappuzzo F, Ligorio C, Janne PA, et al. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization- positive/phospho-Akt-positive or never smoker patiënts with advanced non-small-cell lung cancer: The ONCOBELL trial. J Clin Oncol 25:2248-2255, 2007.

 
79 - Cappuzzo F (2009)
Cappuzzo F, Marchetti A, Skokan M, et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patiënts. J Clin Oncol 27:1667-1674;2009.
 
80 - Jiang J (2007)
Jiang J, Liang X, Zhou X, et al: A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer. Lung Cancer 57:348-358, 2007.
 
81 - Carlson JJ (2009)
Carlson JJ, Garrison LP, Ramsey SD, Veenstra DL. Epidermal growth factor receptor genomic variation in NSCLC patiënts receiving tyrosine kinase inhibitor therapy: a systematic review and meta-analysis. J Cancer Res Clin Oncol 135:1483-1493, 2009.
 
82 - Cerfolio RJ (1996)
Cerfolio RJ, Allen MS, Trastek VF, Deschamps C, Scanlon PD, Pairolero PC. Lung resection in patiënts with compromised pulmonary function. Ann Thorac Surg 62:348-351, 1996
 
83 - Cerfolio RJ (2004)
Cerfolio RJ, Ojha B, Bryant AS, Raghuveer V, Mountz JM, Bartolucci AA. The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patiënts with nonsmall cell lung cancer. Ann Thorac Surg 78:1017-1023, 2004.
 
84 - Cerfolio RJ (2006)
Cerfolio RJ, Bryant AS, Eloubeidi MA. Routine mediastinoscopy and esophageal ultrasound fine-needle aspiration in patiënts with non-small cell lung cancer who are clinically N2 negative: a prospective study. Chest.130:1791-1795,2006.
 
85 - Chansky (2009)
Chansky, Kari; Sculier, Jean-Paul; Crowley, John J.; Giroux, Dori; Van Meerbeeck, Jan; Goldstraw, Peter; on behalf of the International Staging Committee and Participating Institutions. The International Association for the Study of Lung Cancer Staging Project: Prognostic Factors and Pathologic TNM Stage in Surgically Managed Non-small Cell Lung Cancer. J Thor Oncol 4(7):792-801, 2009.
 
86 - Chee KG (2008)
Chee KG, Nguyen DV, Brown M, Gandara DR, Wun T, Lara PN., Jr Positron emission tomography and improved survival in patiënts with lung cancer: the Will Rogers phenomenon revisited. Arch Intern Med 168:1541–1549, 2008.
 
87 - Non-small Cell Lung Cancer Collaborative Group. (1995)
Non-small Cell Lung Cancer Collaborative Group. No authors listed. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patiënts from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ ;311: 899-909,1995.
 
88 - Chen ZL (1993)
Chen ZL, Perez S, Holmes EC, Wang HJ, Coulson WF, Wen DR, et al. Frequency and distribution of occult micrometastases in lymph nodes of patiënts with non-small-cell lung carcinoma. J Natl Cancer Inst 85:493-498, 1993.
 
89 - Chevalier T le (1991)
Chevalier T le, Arriagada R, Quoix E, Ruffie P, Martin M, Tarayre M, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in non-resectable non-small-cell lung cancer: First analysis of a randomized trial in 353 patiënts. J Natl Cancer Inst 83:417-423, 1991.
 
90 - Chevalier T le (1994)
Chevalier T le, Brisgand D, Douillard JY, Pujol JL, Alberola W, Monnier A, et al. Randomized study of vinorelbine and cisplatin versus vindesine plus cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patiënts. J Clin Oncol 12:360-367, 1994.
 
91 - Chi A (2010)
Chi A, Liao Z, Nguyen NP, Xu J, Stea B, Komaki R. Systemic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small-cell lung cancer: clinical implications. Radiother Oncol 94:1-11, 2010.
 
92 - Hotta K (2004)
Hotta K, Matsuo K, Ueoka H, et al: Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patiënts with advanced non–small-cell lung cancer. J Clin Oncol 22:3852-3859, 2004.
 
93 - Ciuleanu T (2009)
Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. The Lancet 374:1432-1440; 2009.
 
94 - Clamon G (1999)
Clamon G, Herndon J, Cooper R, Chang AY, Rosenman J, Green MR. Radiosensitization with carboplatin for patiënts with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. J Clin Oncol 1999;17:4-11, 1999.
 
95 - Clamon G (1994)
Clamon G, Herndon J, Eaton W et al. A feasibility study of extended chemotherapy for locally advanced non-small cell lung cancer: a phase II trial of Cancer and Leukemia Group B. Can Inv 12:273-282, 1994.
 
96 - Coate LE (2009)
Coate LE, John TH, Tsao M-S, Shepherd FA. Molecular predictive and prognostic markers in non-small-cell lung cancer. the Lancet Oncology 10:1001 - 1010, 2009.
 
97 - Colice GL (2003)
Colice GL, Rubins J, Unger M. Follow-up and surveillance of the lung cancer patiënt following curative-intent therapy. Chest 123:272283, 2003.
 
98 - Begg C.B. (1998)
Begg C.B., PhD; Laura D. Cramer, ScM; William J. Hoskins, MD; Murray F. Brennan, MD. Impact of Hospital Volume on Operative Mortality for Major Cancer Surgery. JAMA 280:1747-1751, 1998.
 
99 - Commissie Beroeps Uitoefening (2000)
Commissie Beroeps Uitoefening CBU. Nederlandse Vereniging voor Pathologie. Protocol Longcarcinoom.
 
100 - NVRO (2002)
Commissie voor beroepsaangelegenheden van de Nederlandse Vereniging voor Radiotherapie en Oncologie NVRO. Algemene normstelling voor wachttijden in de radiotherapie die uitgaande van de ‘ideale situatie’in alle afdelingen voor radiotherapie in Nederland van toepassing zou moeten zijn. Utrecht: NVRO, 2002.
 
101 - Common Therapy Evaluation Program CTEP (1998)
Common Therapy Evaluation Program CTEP. Common Toxicity Criteria. Version 2.0. DCTD, NCI, NIH, DHHS, 1998.
 
102 - Cook GJ (1998)
Cook GJ, Houston S, Rubens R, Maisey MN, Fogelman I. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 16:3375-3379, 1998.
 
103 - Sause W (2000)
Sause W, Kolesar P, Taylor S, Johnson D. Final results of phase III trial in regionally advanced unresectable nonsmall cell lung cancer: Radiation Therapy Oncology group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 117:358-364, 2000.
 
104 - Corris PA (1987)
Corris PA, Ellis DA, Hawkins T, Gibson GJ. Use of radionuclide scanning in the preoperative evaluation of pulmonary function after pneumonectomy. Thorax 42:285-291, 1987.
 
105 - Costa DB (2007)
Costa DB, Kobayashi S, Tenen DG, et al: Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer 58:95-103, 2007.
 
106 - Coughlin M (1985)
Coughlin M, Deslauriers J, Beaulieu M, Fournier B, Piraux M, Rouleau J, et al. Role of mediastinoscopy in pre-treatment staging of patiënts with primary lung cancer. Ann Thorac Surg 40:556-560 1985.
 
107 - Cox JD (1990)
Cox JD, Azarnia N, Byhardt RW, Shin KH, Emami B, Pajak TF. A randomised phase I-II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with > 69.6 Gy in favourable patiënts with radiation therapy oncology group stage III non-small cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11. J Clin Oncol 8:543-555, 1990.
 
108 - Cox JD (1979)
Cox JD. Patterns of failure followingg treatment of apparently localized carcinoma of the lung. In: Muggia FM Rozencwieg M (eds). Lung cancer; progress in therapeutic research. Vol 11. New York: Raven, 279-328, 1979.
 
109 - Cox K (2006)
Cox K, Wilson E, Heath L, Collier J, Jones L, Johnston I. Preferences for follow-up after treatment for lung cancer: Assessing the nurse-led option. Cancer Nursing 2006, vol 29, no3, 176-187.
 
111 - Crabtree TD (2010)
Crabtree TD, Denlinger CE, Meyers BF, El Naqa I, Zoole J, Krupnick AS, Kreisel D, Patterson GA, Bradley JD. Stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 140:377-386, 2010.
 
112 - Cullen MH (2008)
Cullen MH, Zatloukal P, Sorenson S, et al: A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patiënts with locally advanced or metastatic nonsmall-cell lung cancer. Ann Oncol 19:939-945, 2008.
 
113 - Curran WJ (2003)
Curran WJ, Scott CB, Langer CJ, et al. Long-term benefit is observed in a phase III comparison of sequential vs concomitant chemo-radiation for patiënts with unresected stage III NSCLC: RTOG 9410. Proc Am Soc Clin Oncol 22: 621-621, 2003.
 
114 - Cybulsky IJ (1994)
Cybulsky IJ, Bennet WF. Mediastinoscopy as a routine outpatiënt procedure. Ann Thorac Surg 58:176-178, 1994.
 
115 - D’Addario G (2005)
D’Addario G,Pintilie M, Leighl NB, et al. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 2005;23:2926-2936.
 
116 - Dahabreh IJ (2010)
Dahabreh IJ, Linardou H, Siannis F, Kosmidis P, Bafaloukos D, Murray S. Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer. Clin. Cancer Res 16:291-303, 2010.
 
117 - Dahabreh J (2010)
Dahabreh J, Linerdou H, Kosmidis P, Bafaloukos D, Murray S. EGFR gene copy number as a predictive biomarker for patiënts receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer. Ann of Oncol sept 8, 2010.
 
118 - Dahse R (2009)
Dahse R, Driemel O, Schwarz S, et al. Epidermal growth factor receptor kinase domain mutations are rare in salivary gland carcinomas. Br. J. Cancer 100:623-625, 2009.
 
119 - Dahse R (2008)
Dahse R, Kosmehl H. Detection of drug-sensitizing EGFR exon 19 deletion mutations in salivary gland carcinoma. Br J Cancer 99:90-92, 2008.
 
120 - Damhuis RA (1996)
Damhuis RA, Schutte PR. Resection rates and postoperative mortality in 7899 patiënts with lung cancer. Eur Respir J 9:97-100, 1996.
 
121 - Dartevelle P (1995)
Dartevelle P, Macchiarini P, Chapelier A. Tracheal ‘sleeve’-pneumonectomy. Ann Thorac Surg 60:1854-5 1995.
 
122 - Dartevelle PG (1993)
Dartevelle PG, Chapellier AR, Macchiarini P, Lenot B, Cerrina J, Ladurie FL, et al. Anterior transcervical-thoracic approach for radical resection of lungtumors invading the thoracic inlet. J Thorac Cardiovasc Surg 105:1025-1034, 1993.
 
123 - Dartevelle PG (1997)
Dartevelle PG. Herbert Sloan Lecture: Extended operations for the treatment of lung cancer. Ann Thorac Surg 63:2-19, 1997.
 
124 - Davidoff AJ (2010)
Davidoff AJ, Tang M, Seal B, Edelman MJ. Chemotherapy and survival benefit in elderly patiënts with advanced Non–Small-Cell Lung Cancer. J Clin Oncol 28:2191-2197, 2010.
 
125 - de Perrot M (1999)
de Perrot M, Licker M, Reymond MA, Robert J, Spiliopoulos A. Influence of age on operative mortality and longterm survival after lung resection for bronchogenic carcinoma. Eur Respir J 14:419-422, 1999.
 
126 - De Ruysscher D (2010)
De Ruysscher D, Faivre-Finn C, Nestle U, Coen W, et al. European organization for Rearch and treatment of cancer recommendations for planning and delivary of high-dose, hgh precision radiotherapy for lung cancer. J Clin Oncol. 2010 Dec 20;28(36):5301-10.
 
127 - Deegan PC (1998)
Deegan PC, Heath L, Brunskill J, Kinnear WJ, Morgan SA, Johston IDA. Reducing waiting times in lung cancer. Journal of the Royal College of Physicans of London 32:339-343, 1998.
 
128 - Dehing-Oberije C (2009)
Dehing-Oberije C, Yu S, de Ruysscher D et al. Development and external validation of prognostic model for 2-year survival of non-small-cell lung cancer patiënts treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys 74:355-362; 2009.
 
129 - Delbaldo C (2009)
Delbaldo C, Michiels S, Rolland E, et al. Second and third additional chemotherapy drug for non-small cell lung cancer in patiënts with advanced disease (Review). Cochrane Database of Systematic Reviews 2009;3:1-71.
 
131 - Delbeke D (1998)
Delbeke D, Martin WH, Sandler MP, Chapman WC, Wright JK, Pinson CW. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg 133:510-515, 1998.
 
132 - Demmy (1997)
Demmy, TL, Wagner-Mann, CC, James, MA, et al Feasibility of mathematical models to predict success in video-assisted thoracic surgery lung nodule excision. Am J Surg ;174,20-23,1997.
 
133 - Deneffe G (1983)
Deneffe G, Lacquet LM, Gyselen A. Cervical mediastinoscopy and anterior mediastinotomy in patiënts with lung cancer and radiologically normal mediastinum. Eur J Respir Dis 64:613-619, 1983.
 
134 - DeRose-JJ Jr (1998)
DeRose-JJ Jr, Argenziano M, El Amir N, Jellen PA, Gorenstein LA, Steinglass KM, et al. Lung reduction operation and resection of pulmonary nodules in patiënts with severe emphysema. Ann Thorac Surg 65:314-318, 1998
 
135 - Deslauriers J (2004)
Deslauriers J, Gregoire J, Jacques LF, Piraux M, Guojin L, Lacasse Y. ‘sleeve’-lobectomy versus pneumonectomy for lung cancer: a comparative analysis of survival and sites of recurrences. Ann Thorac Surg 77:1152-1156; discussion 1156, 2004.
 
136 - Detterbeck FC (2001)
Detterbeck FC, Jones DR, Funkhouser WK Jr. Satellite nodules and multiple primary cancers. In: Detterbeck FC, Rivera MP, Socinski MA, Rosenman J (eds). Diagnosis and treatment of lung cancer: An evidence-based guide for the practising clinician. Philadelphia: Saunders, 437-449, 2001
 
137 - Detterbeck FC (2001)
Detterbeck FC, Jones DR. Surgery for stage IIIb non-small cell lung cancer. In: Detterbeck FC, Rivera MP, Socinski MA, Rosenman J (eds). Diagnosis and treatment of lung cancer: An evidence-based guide for the practicing clinician. Philadelphia: Saunders 283-289, 2001.
 
138 - Devine EC (1995)
Devine EC, Westlake SK. Physical exercise and quality of life following cancer diagnosis: a literature review. Ann Behav Med 21:171-179, 1995.
 
139 - Di Maio M (2009)
Di Maio M, Chiodini P, Georgoulias V, et al. Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 27:1836-1843, 2009.
 
140 - Di Maio M (2010)
Di Maio M, Lama N, Morabito A, et al. Clinical assessment of patiënts with advanced non-small-cell lung cancer eligible for second-line chemotherapy: A prognostic score from individual data of nine randomised trials. Eur J Cancer 46: 735-743, 2010.
 
141 - Di Maio M (2003)
Di Maio M, Perrone F, Gallo C, Iaffaioli RV, Manzione L, Piantedosi FV, Cigolari S, Illiano A, Barbera S, Robbiati SF, Piazza E, Ianniello GP, Frontini L, Veltri E, Castiglione F, Rosetti F, De Maio E, Maione P, Gridelli C. Supportive care in patiënts with advanced non-small-cell lung cancer. Br J Cancer 89: 1013–1021, 2003.
 
142 - Diamandis EP (2010)
Diamandis EP. Cancer biomarkers: can we turn recent failures into success? J Natl Cancer Inst 102:1-6, 2010.
 
143 - Dienemann H (1997)
Dienemann H, Trainer C, Hoffmann H, Bulzebruck, Muley T, Kayser K, et al. Inkomplette Resektionen bei Bronchialcarcinom: Morbiditat und Prognose. Chirurg 68:1014-1019, 1997.
 
144 - Dillman RO (1996)
Dillman RO, Herndon J, Seagren SL, Eaton W-LJ, Green MR. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 88:1210-1215, 1996.
 
145 - Dillman RO (1990)
Dillman RO, Seagren SL, Propert KJ, Guerra J, Eaton WL, Perry MC, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 323:940-945 , 1990.
 
146 - Dimick JB (2003)
Dimick JB, Pronovost PJ, Cowan Ja, Lipsett PA. Surgical volume and quality of care for esophageal resection: high volume hospitals have fewer complications. Ann Thorac Surg 75:337-341, 2003.
 
147 - Dobashi K (1997)
Dobashi K, Sugio K, Osaki T, Oka T, Yasumoto K. Micrometastatic P53-positive cells in the lymph nodes of nonsmall-cell lung cancer: prognostic significance. J Thorac Cardiovasc Surg 114:339-346, 1997.
 
148 - Dosoretz DE (1993)
Dosoretz DE, Galmarini D, Rubenstein JH, Katin MJ, Blitzer PH, Salenius SA, et al. Local control in medically inoperable lung cancer: an analysis of its importance in outcome and factors determining the probability of tumor eradication. Int J Radiat Oncol Biol Phys 27:507-516, 1993.
 
149 - Douillard JY (2006)
Douillard JY, Rosell R, De Lena M, Carpagnano F, et al. Adjuvant vinorelbine plus cisplatin versus observation in patiënts with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 7,719-727, 2006.
 
150 - Douillard JY (2010)
Douillard JY, Shepherd FA, Hirsh V, et al. Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non-Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial. J. Clin. Oncol 28:744-752, 2010.
 
151 - Downey R (1999)
Downey R, Martini N, Rusch V, Bains M, Korst R, Ginsberg R. Extent of chest wall invasion and survival in patiënts with lung cancer. Ann Thorac Surg 68:188-193,1999.
 
152 - Dresler CM (1999)
Dresler CM, Fratelli C, Babb J. Prognostic value of positive pleural lavage in patiënts with lung cancer resection. Ann Thorac Surg 67:1435-439, 1999.
 
153 - Dwamena BA (1990)
Dwamena BA, Sonnad SS, Angobaldo JO, Wahl RL. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s--meta-analytic comparison of PET and CT. Radiology 213:530-536,1999.
 
154 - Eagle KA (2002)
Eagle KA, Berger PB, Calkins H, Chaitman BR, Ewy GA, Fleischmann KE, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery – executive summary. Circulation 105:1257-1267, 2002.
 
155 - Ebner H (1999)
Ebner H, Marra A, Butturini E, Santis F de. Clinical value of cervical mediastinoscopy in the staging of bronchial carcinoma. Ann Ital Chir 70:873-879, 1999
 
156 - Edelman MJ (1997)
Edelman MJ, Meyers FJ, Siegel D. The utility of follow-up testing after curative cancer therapy. A critical review and economic analysis. J Gen Intern Med 12:318-331, 1997.
 
157 - Edelman MJ (2002)
Edelman MJ, Schuetz J. Follow-up of local (stage I and stage II) non-small-cell lung cancer after surgical resection. Curr Treat Options Oncol 3:67-73, 2002.
 
158 - Edelman MJ (2008)
Edelman MJ, Suntharalingam M, Burrows W, Kwong KF, Mitra N, Gamliel Z, et al. Phase I/II trial of hyperfractionated radiation and chemotherapy followed by surgery in stage III lung cancer. Ann Thorac Surg 86:903-910; 2008.
 
159 - Edwards JG (2001)
Edwards JG, Duthie DJ, Waller DA. Lobar volume reduction surgery: a method of increasing the lung cancer resection rate in patiënts with emphysema. Thorax 56:791-795, 2001
 
160 - Effenberger KE (2007)
Effenberger KE, Sienel W, Pantel K. Lymph node micrometastases in lung cancer. Cancer Treat Res ;135:167-175, 2007.
 
161 - Egermann U (2002)
Egermann U, Jaeggi K, Habicht JM, Perruchoud AP, Dalquen P, Soler M. Regular follow-up after curative resection of nonsmall lung cancer: a real benefit for patiënt? Eur Respir J 19:464-468, 2002.
 
162 - El Sharouni SY (2008)
El Sharouni SY, Schramel FMNH, Vonk EJA, De Ruysscher DKM, Senan S, Aerts JGJV, Paul MA, Smit EF, Groen HJM, Verhagen AF. Longkanker: Uitstel van bestraling - radiotherapie na chemo leidt tot signicant kortere levensduur en vroegtijdige sterfte aan niet-klein-cellige longkanker en meer ongeneeslijke longkankeripatiënten. Ned. Tijdschrift Geneeskunde 152;2714-2717, 2008.
 
163 - Elia S (2001)
Elia S, Griffo S, Gentile M, Costabile R, Ferrante G. Surgical treatment of lung cancer invading the chest wall: a retrospective analysis of 110 patiënts. Eur J Cardiothorac Surg 20:356-60, 2001.
 
164 - El-Sherif A (2006)
El-Sherif A, Gooding WE, Santos R, et al. Outcomes of sublobar resection versus lobectomy for stage I non-small cell lung cancer: A 13-year analysis. Ann Thorac Surg 82:408–415, discussion 415-416, 2006.
 
165 - Emami B (2003)
Emami B, Mirkovic N, Scott C, Byhardt R, Graham MV, James Andras E, et al. The impact of regional nodal radiotherapy (dose/volume) on regional progression and survival in unresectable non-small cell lung cancer: an analysis of RTOG data. Lung Cancer 41:207-214, 2003.
 
166 - Sutani A (2006)
Sutani A, Nagai Y, Udagawa K, et al. Gefitinib for non-small-cell lung cancer patiënts with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. Br J Cancer 95:1483-1489, 2006.
 
167 - Erasmus JJ (1997)
Erasmus JJ, Patz E-FJ, McAdams HP, Murray JG, Herndon J, Coleman RE, et al. Evaluation of adrenal masses in patiënts with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. Am J Roentgenol 168:1357-1360, 1997.
 
168 - Errett LE (1985)
Errett LE, Wilson J, Chiu RC, Munro D. Wedge resection as an alternative procedure for peripheral bronchogenic carcinoma in poor-risk patiënts. Thorac Cardiovasc Surg 90:656-661, 1985.
 
169 - Extermann M (1998)
Extermann M, Overcash J, Lyman GH, Parr J, Balducci L. Comorbidity and functional status are independent in older cancer patiënts. J Clin Oncol 16:1582-587, 1998.
 
170 - Cappuzzo F (2007)
Cappuzzo F, Ligorio C, Janne PA, et al. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization– positive/phospho-Akt–positive or never smoker patiënts with advanced non–small-cell lung cancer: The ONCOBELL trial. J Clin Oncol 25:2248-2255, 2007.
 
171 - Fadel E (2002)
Fadel E, Yildizeli B, Chapelier A, Dicenta I, Mussot S, Dartevelle P. ‘Sleeve’-lobectomy for bronchogenic cancers: factors affecting survival. Ann Thor Surg 74:851-858, 2002.
 
172 - Fakiris AJ (2009)
Fakiris AJ, McGarry RC, Yiannoutsos CT, et al. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: Four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys 75:677–682, 2009.
 
173 - Falk SJ (2002)
Falk SJ, Girling DJ, White RJ, Hopwood P, Harvey A, Qian W, et al, on behalf of the Medical Research Council Lung Cancer Working Party. Immediate versus delayed palliative thoracic radiotherapy in patiënts with unresectable locally advanced non-small cell lung cancer and minimal thoracic symptoms: randomised controlled trial. BMJ 325:465-468, 2002.
 
174 - Feld R (1991)
Feld R, Arriagada R, Ball DL, Mattson K, Sorensen JB. Prognostic factors in non-small cell lung cancer: a consensus report. Lung Cancer 7:3-5, 1991.
 
175 - Ferguson MK (2000)
Ferguson MK, Karrison T. Does pneumonectomy for lung cancer adversely influence long-term survival? J Thorac Cardiovasc Surg 119:440-8, 2000.
 
176 - Ferguson MK (2003)
Ferguson MK, Lehman AG. ‘sleeve’-lobectomy or pneumonectomy: optimal management strategy using decision analysis techniques. Ann Thorac Surg 76:1782-1788, 2003.
 
177 - Ferguson MK (1988)
Ferguson MK, Little L, Rizzo L, Popovich KJ, Glonek GF, Leff A, et al. Diffusing capacity predicts morbidity and mortality after pulmonary resection. J Thorac Cardiovasc Surg 96:894-900, 1988.
 
178 - Ferguson MK (1995)
Ferguson MK. Optimizing selection of patiënts for major lung resection. J Thorac Cardiovasc Surg 109:275-281; discussion 281-3, 1995.
 
179 - Feuer EJ (1999)
Feuer EJ, Sheinfeld J, Bosl GJ. Does size matter? Association between number of patiënts treated and patiënt outcome in metastatic testicular cancer. J Natl Cancer Inst 91:816-818, 1999.
 
180 - Feuer EJ (1999)
Feuer EJ, Sheinfeld J, Bosl GJ. Does size matter? Association between number of patiënts treated and patiënt outcome in metastatic testicular cancer. J Natl Cancer Inst 91:816-818, 1999.
 
181 - Fidias PM (2009)
Fidias PM, Dakhil SR, Lyss AP, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non–small-cell lung cancer. J Clin Oncol 27:591-598, 2009.
 
182 - Firat S (2002)
Firat S, Bousamra M, Gore E, Byhardt RW. Comorbidity and KPS are independent prognostic factors in stage I nonsmall- cell lung cancer. Int J Radiat Oncol Biol Phys 52:1047-1057, 2002.
 
183 - Firat S (2002)
Firat S, Byhardt RW, Gore E. Comorbidity and Karnofksy performance score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patiënts treated on four RTOG studies. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 54:357-364, 2002.
 
184 - Fischer B (2009)
Fischer B, Lassen U, Mortensen J, Larsen S, Loft A, Bertelsen A, Ravn J, Clementsen P, Høgholm A, Larsen K, Rasmussen T, Keiding S, Dirksen A, Gerke O, Skov B, Steffensen I, Hansen H, Vilmann P, Jacobsen G, Backer V, Maltbaek N, Pedersen J, Madsen H, Nielsen H, Højgaard L. Preoperative staging of lung cancer with combined PET-CT. N Engl J Med 361:32-39, 2009.
 
185 - Fong Y (1999)
Fong Y, Saldinger PF, Akhurst T, Macapinlac H, Yeung H, Finn RD, et al. Utility of 18F-FDG positron emission tomography scanning on selection of patiënts for resection of hepatic colorectal metastases. Am J Surg 178:282-287, 1999 .
 
186 - Fossella F (2003)
Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non–small-cell lung cancer: The TAX 326 study group. J Clin Oncol 21:3016-3024, 2003.
 
187 - Fossella FV (2000)
Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patiënts with advanced non-small-cell lung cancer previously treated platinum-containing chemotherapy regimens.The TAX 320 Non-Small-Cell-Lung Cancer Study Group. J Clin Oncol 18:2354-2362, 2000.
 
188 - Fournel P (2005)
Fournel P, Robinet G, Thomas P, et al. Randomized phase III trial of sequential chemoradiotherapy compared with concomitant chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol 223: 5910-5917, 2005
 
189 - Fowler JF (2004)
Fowler JF, Welsh JS, Howard SP. Loss of biological effect in prolonged fraction delivery. Int J Radiat Oncol Biol Phys 59:242-249, 2004.
 
190 - Fujino S (2000)
Fujino S, Inoue S, Tezuka N, Kontani K, Sawai S, Hanaoka. Results of combined resection of adjacent organs in lung cancer. Thorac Cardiovasc Surg 48:130-133, 2000.
 
191 - Fukui T (2007)
Fukui T, Tsuta K, Furuta K, et al. Epidermal growth factor receptor mutation status and clinicopathological features of combined small cell carcinoma with adenocarcinoma of the lung. Cancer Sci 98:1714-1719, 2007.
 
192 - Funkhouser WK Jr (2001)
Funkhouser WK Jr. Satellite nodules and multiple primary cancers. In: Detterbeck FC, Rivera MP, Socinski MA, Rosenman J (eds). Diagnosis and treatment of lung cancer: An evidence-based guide for the practising clinician. Philadelphia: Saunders, 437-449, 2001.
 
193 - Furuse K (1999)
Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concomitant versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17:2692-2699, 1999.
 
194 - Gaer JAR (1990)
Gaer JAR, Goldstraw P. Intraoperative assessment of nodal staging at thoracotomy for carcinoma of the bronchus. Eur J Cardiothorac Surg 4:207-210, 1990.
 
195 - Garfiels DH (2005)
Garfiels DH. Modern treatment of lung cancer: response to erlotinib after failure of gefitinib in a patiënt with advanced non-small cell lung carcinoma. J Clin Oncol 23:7738-7740, 2005.
 
196 - Gatzemeier U (2007)
Gatzemeier U, Pluzanska A, Szczesna A, Eckhard Kaukel E, et al. Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non–Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial. J Clin Oncol 25:1545-1552, 2007.
 
197 - Gdeedo A (1997)
Gdeedo A, Schil P van, Corthouts B, Mieghem F van, Meerbeeck J van, Marck E van, et al. Prospective evaluation of computed tomography and mediastinoscopy in mediastinal lymph node staging. Eur Respir J 10 :1547-1551 1997.
 
198 - Gebitekin C (1994)
Gebitekin C, Gupta NK, Satur CM, Olgac G, Martin PG, Saunders NR, et al. Fate of patiënts with residual tumour at the bronchial resection margin. Eur J Cardiothorac Surg 8:339-342; discussion 342-4, 1994.
 
199 - Gephardt GN (1996)
Gephardt GN, Baker PB. Lung carcinoma surgical pathology rapport adequacy . Arch Path Lab Med 120:922-927, 1996.
 
200 - Ghiribelli C (2002)
Ghiribelli C, Voltolini L, Luzzi L, Paladini P, campione A, Gotti G. Survival after bronchoplastic lobectomy for non small cell lung cancer compared with pneumonectomy according to nodal status. J cardiovasc Surg (Torino) 43:103-108, 2002.
 
201 - Ghiribelli C (1999)
Ghiribelli C, Voltolini L, Paladini P, Luzzi L, Bisceglie M di, Gotti G. Treatment and survival after lung resection for non-small cell lung cancer in patiënts with microscopic residual disease at the bronchial stump. Eur J Cardiothorac Surg 16:555-559, 1999.
 
202 - Giaccone G (2004)
Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non–small-cell lung cancer: A phase III trial—INTACT 1. J Clin Oncol 22:777-784, 2004.
 
203 - Gibbs AR (2007)
Gibbs AR, Nicholson AG on behalf of the RCPath Cancer Services Working Group. The Royal College of Pathologists. Standards and Datasets for Reporting Cancers. Dataset for lung cancer histopathology reports. (2nd edition). September 2007; Minimum data set for lung cancer. Checklist. Second Revision. September 2010.
 
204 - Gilbert S (2000)
Gilbert S, Reid KR, Lam MY, Petsikas D. Who should follow-up lung cancer patiënts after operation? Ann Thorac Surg 69:1696-1700, 2000.
 
205 - Ginsberg R (1983)
Ginsberg R, Lucius D, Eagan R, Thomas P, Mountain C, Deslaurirs J, et al. Modern thirty-day operative mortality for surgical resections in lung cancer. J Thorac Cardiovasc Surg 86:654-658, 1983.
 
206 - Ginsberg RJ (1995)
Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 60:615–622, discussion 622-623, 1995.
 
207 - Giroux (2009)
Giroux, Dorothy J.; Rami-Porta, Ramón; Chansky, Kari; Crowley, John J.; Groome, Patti A.; Postmus, Pieter E.; Rusch, Valerie; Sculier, Jean-Paul; Shepherd, Frances A.; Sobin, Leslie; Goldstraw, Peter; On behalf of the International Association for the Study of Lung Cancer International Staging Committee. The IASLC Lung Cancer Staging Project: Data Elements for the Prospective Project. J Thor Oncol 4(6):679-683, 2009.
 
208 - Goldstraw P (2009)
Goldstraw P. Staging Manual in Thoracic Oncology. International Association for the Study of Lung Cancer. Editorial Rx Press, Orange Park, Florida, USA, 2009.
 
209 - Goldstraw (2007)
Goldstraw, Peter; Crowley, John; Chansky, Kari; Giroux, Dorothy J.; Groome, Patti A.; Rami-Porta, Ramon; Postmus, Pieter E.; Rusch, Valerie; Sobin, Leslie; on behalf of the International Association for the Study of Lung Cancer International Staging Committee and Participating Institutions. The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours. J Thor Oncol 2(8):706-714, 2007.
 
210 - Gonzalez Stawinski GV (2003)
Gonzalez Stawinski GV, Lemaire A, Merchant F, O'Halloran E, Coleman RE, Harpole DH, et al. A comparative analysis of positron emission tomography and mediastinoscopy in staging non-small cell lung cancer. J Thorac Cardiovasc Surg 126:1900-1905, 2003.
 
211 - Goss G (2009)
Goss G, Ferry D, Wierzbicki R, Laurie SA, Thompson J, Biesma B, Hirsch FR, Varella-Garcia M, Duffield E, Ataman OU, Zarenda M, Armour AA. Randomized Phase II Study of GefitinibCompared With Placebo in Chemotherapy-Naive Patiënts With Advanced Non–Small-Cell Lung Cancer and Poor Performance Status J Clin Oncol 27:2253-2260, 2009.
 
212 - Gould MK (2001)
Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 285:914-924, 2001
 
213 - Gould MK (2003)
Gould MK, Kuschner WG, Rydzak CE, Maclean CC, Demas AN, Shigemitsu H, et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patiënts with non-small-cell lung cancer: a meta-analysis. Ann Intern Med 139:879-892, 2003.
 
214 - Gould MK (2001)
Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 285:914-924, 2001
 
215 - Graeter TP (2003)
Graeter TP, Hellwig D, Hoffmann K, Ukena D, Kirsch CM, Schafers HJ. Mediastinal lymph node staging in suspected lung cancer: comparison of positron emission tomography with F-18-fluorodeoxyglucose and mediastinoscopy. Ann Thorac Surg 75:231-235, 2003.
 
216 - Gray RE (1997)
Gray RE, Fitch MI, Phillips C, Labrecque M, Klotz L. Presurgery experiences of prostate patiënts and their spou ses. Cancer Pract 7:130-135, 1997.
 
217 - Greene FL (2002)
Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, et al (eds). AJCC Cancer Staging manual. 6th edition. New York: Springer-Verlag, 167-77, 2002.
 
218 - Gregor A (1993)
Gregor A, Macbeth FR, Paul J, Cram L. Radical radiotherapy and chemotherapy in localized inoperable non-smallcell lung cancer: a randomised trial. J Natl Cancer Inst 85:997-999, 1993.
 
219 - Greschuchna D (1973)
Greschuchna D, Maassen W. Die Lymphogenen Absiedlungswege des Bronchialkarzinoms. Stuttgart: Thieme, 1973.
 
220 - Gridelli C (2004)

Gridelli C, Ardizzoni A, Le Chavalier T, et al. Treatment of advanced non-small cell  lung cancer patiënts with ECOG performance status 2: results of an European Experts Panel. Ann Oncol 2004;15:419-426.

 
221 - Gridelli C (2003)
Gridelli C, Perrone F, Gallo C, Cigolari S, Rossi A, Piantedosi F, et al. Chemotherapy for elderly patiënts with advanced non-small-cell lung cancer: the multicenter Italian lung cancer in the elderly study (MILES) phase III randomized trial. J Natl Cancer Inst 95:362-372, 2003.
 
222 - Grills IS (2010)
Grills IS, Mangona VS, Welsh R, et al. Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non–small-cell lung cancer (NSCLC) J Clin Oncol 28:928–935, 2010.
 
223 - Grol BMF (2001)
Grol BMF, Bennebroek FTC, Vos D. Psycho-educatief programma voor kankerpatienten: Cursus ‘Omgaan met kanker’. In: Haes JCJM de, Gualtherie van Weezel LM, Sanderman R, Wiel HBM van der (red). Psychologische patiëntenzorg in de oncologie; handboek voor de professional. Assen: Van Gorcum, 154-160, 2001.
 
224 - Grønberg BH (2009)
Grønberg BH, Bremnes RM, Fløtten Ø, et al. Phase III study by the Norwegian Lung Cancer Study Group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non–small-cell lung cancer. J Clin Oncol 2009;27:3217-3224.
 
225 - Groome (2007)
Groome, Patti A.; Bolejack, Vanessa; Crowley, John J.; Kennedy, Catherine; Krasnik, Mark; Sobin, Leslie H.; Goldstraw, Peter; on Behalf of the International Staging Committee, Cancer Research and Biostatistics, Observers to the Committee and Participating Institutions. The IASLC Lung Cancer Staging Project: Validation of the Proposals for Revision of the T, N, and M Descriptors and Consequent Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours. J Thor Oncol 2(8):694-705, 2007.
 
226 - Grunenwald D (2002)
Grunenwald D, Mazel C, Girard P, Veronesi G, Spaggiari L, Gossot D, et al. Radical en bloc resection for lung cancer invading the spine. J Thorac Cardiovasc Surg 123:271-279, 2002.
 
227 - Gu CD (2002)
Gu CD, Osaki T, Oyama T, Inoue M, Kodate M, Dobashi K, et al. Detection of micrometastatic tumor cells in pN0 lymph nodes of patiënts with completely resected nonsmall cell lung cancer: impact on recurrence and Survival. Ann Surg 235:133-139, 2002.
 
228 - Gu P (2009)
Gu P, Zhao YZ, Jiang LY, Zhang W, Xin Y, Han BH. Endobronchial ultrasound-guided transbronchial needle aspiration for staging of lung cancer: a systematic review and meta-analysis. Eur J Cancer ;45:1389-1396, 2009.
 
229 - Gupta R (2009)
Gupta R, Dastane AM, Forozan F, Riley-Portuguez A, Chung F, Lopategui J, Marchevsky AM. Evaluation of EGFR abnormalities in patiënts with pulmonary adenocarcinoma: the need to test neoplasms with more than one method. Mod Pathol 22:128-133, 2009.
 
230 - Guyatt GH (1999)
Guyatt GH, Cook DJ, Griffith LE, Miller JD, Todd TR, Johnston MR, et al. Surgeons’ assessment of symptoms suggesting extrathoracic metastases in patiënts with lung cancer. Ann Thorac Surg 68:309-15, 1999.
 
231 - H (2006)
H, Sun Q, Wang Y, Fan N, Yu Y, Li P, Chang JY. Promising clinical outcome of stereotactic body radiation therapy for patiënts with inoperable Stage I/II non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 66:117-125, 2006.
 
232 - Haasbeek CJ (2010)
Haasbeek CJ, Lagerwaard FJ, Antonisse ME, Slotman BJ, Senan S. Stage I nonsmall cell lung cancer in patiënts aged > or =75 years: outcomes after stereotactic radiotherapy. Cancer 116:406-4014, 2010.
 
233 - Haasbeek CJ (2008)
Haasbeek CJ, Senan S, Smit EF, Paul MA, Slotman BJ, Lagerwaard FJ. Critical review of nonsurgical treatment options for stage I non-small cell lung cancer. Oncologist 13:309-319, 2008.
 
234 - Hainsworth JD (2007)
Hainsworth JD, Spigel DR, Farley C, et al. Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patiënts with advanced non-small cell lung cancer: A randomized phase 3 trial of the Minnie Pearl Cancer Research Network. Cancer 110:2027-2034, 2007.
 
235 - Hammoud (1999)
Hammoud, ZT, Anderson, RC, Meyers, BF, Guthrie TJ, Roper CL, Cooper JD, et al The current role of mediastinoscopy in the evaluation of thoracic disease. Thorac Cardiovasc Surg;118:894-899, 1999
 
236 - Han SW (2008)
Han SW, Kim HP, Jeon YK, et al. Mucoepidermoid carcinoma of lung: potential target of EGFR-directed treatment. Lung Cancer 61:30-34, 2008.
 
237 - Hanna N (2004)
Hanna N, Shepherd FA, Fossella FV, et al: Randomized phase III trial of pemetrexed versus docetaxel in patiënts with non–small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589-1597, 2004.
 
238 - Hashimoto T (2000)
Hashimoto T, Kobayashi Y, Ishikawa Y, Tsuchiya S, Okumura S, Nakagawa K, et al. Prognostic value of genetically diagnosed lymph node micrometastasis in non-small cell lung carcinoma cases. Cancer Res 60:6472-6478, 2000.
 
239 - Hayes MM (1993)
Hayes MM, Jones EA, Zhang DY. Diagnoses made by frozen-section examination of surgical specimens in a small Canadian hospital. Can J Surg 36:236-240, 1993.
 
240 - Hayman JA (2001)
Hayman JA, Martel MK, Haken RK ten, Normolle DP, Todd RF 3rd, Littles JF, et al. Dose escalation in non-smallcell lung cancer using three-dimensional conformal radiation therapy: update of a phase I trial. J Clin Oncol 19:127-136, 2001.
 
241 - Heikkila L (1986)
Heikkila L, Harjula A, Suomalainen RJ, Mattila P, Mattila S. Residual carcinoma in bronchial resection line. Ann Chir Gynaecol 75:151-154, 1986.
 
242 - Hensing T (2001)
Hensing T, Halle J, Socinski M. Chemoradiotherapy for stage IIIa, b non-small cell lung cancer. In: Detterbeck F, Rivera M, Socinski M, Rosenman J (eds). Diagnosis and treatment of lung cancer: An evidence-based guide for the practicing clinician. Philadelphia: Saunders, 291-303, 2001.
 
243 - Hensing TA (2003)
Hensing TA, Peterman AH, Schell MJ, et al. The impact of age on toxicity, response rate, quality of life, and survival in patiënts with advanced, stage IIIB or IV non-small cell lung carcinoma treated with carboplatin and paclitaxel. Cancer 98:779-788, 2003.
 
244 - Herbst RS (2004)
Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non–small-cell lung cancer: A phase III trial—INTACT 2. J Clin Oncol 22:785-794,2004.
 
245 - Herbst RS (2005)
Herbst RS, Prager D, Hermann R, et al. TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non–small-cell lung cancer. J Clin Oncol 23:5892-5899, 2005.
 
246 - Herder GJ (2005)
Herder GJ, van Tinteren H, Golding RP, Kostense PJ, Comans EF, Smit EF, Hoekstra OS. Clinical prediction model to characterize pulmonary nodules: validation and added value of 18F-fluorodeoxyglucose positron emission tomography. Chest 128:2490-2496, 2005
 
247 - Herder GJ (2002)
Herder GJ, Verboom P, Smit EF, Velthoven PC van, Bergh JH van den, Colder CD, et al. Practice, efficacy and cost of staging suspected non-small cell lung cancer: a retrospective study in two Dutch hospitals. Thorax 57:11-4, 2002.
 
248 - Herder GJ (2006)
Herder GJ, Kramer H, Hoekstra OS, Smit EF, Pruim J, van Tinteren H, Comans EF, Verboom P, Uyl-de Groot CA, Welling A, Paul MA, Boers M, Postmus PE, Teule GJ,Groen HJ; POORT Study Group. Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study. J Clin Oncol 24:1800-1806, 2006
 
249 - Hermanek P (1994)
Hermanek P, Wittekind C. Residual tumor (R) classification and prognosis. Semin Surg Oncol 10:12-20, 1994.
 
250 - Herth FJ (2006)
Herth FJ, Eberhardt R, Vilmann P, Krasnik M, Ernst A. Real-time endobronchial ultrasound guided transbronchial needle aspiration for sampling mediastinal lymph nodes. Thorax ;61:795-798, 2006.
 
251 - Herth FJ (2010)
Herth FJ, Krasnik M, Kahn N, Eberhardt R, Ernst A. Combined Endoesophageal-Endobronchial Ultrasound-Guided, Fine-Needle Aspiration of Mediastinal Lymph Nodes through a Single Bronchoscope in 150 Patiënts with Suspected Lung Cancer. Chest 2010 Oct;138(4):790-4.
 
252 - Higashiyama M (1997)
Higashiyama M, Doi O, Kodama K, Yokouchi H, Tatcishi R, Horai T, et al. Pleural lavage cytology immediately after thoracotomy and before closure of the thoracic cavity for lung cancer without pleural effusion and dissemination: clinicopathologic and prognostic analysis. Ann Surg Oncol 4:409-415, 1997.
 
253 - Hill KM (2003)
Hill KM, Amir Z, Muers MF, Connolly CK, Round CE. Do newly diagnosed lung cancer patiënts feel their concerns are being met? Eur J of Cancer Care 2003. 12; 35-45.
 
254 - Hill KM (2003)
Hill KM. Do newly diagnosed lung cancer patiënts feel their concerns are being met? Eur J of Cancer Care 2003 Mar;12(1):35-45.
 
255 - Hillerdal G (1998)
Hillerdal G, Dervnik L, Almgren S, Kling P, Gustafsson G. Prognostic value of malignant cells in pleural lavage at thoracotomy for bronchial carcinoma. Lung Cancer 21:47-52, 1998.
 
256 - Hillers TK (1994)
Hillers TK, Sauve MD, Guyatt GH. Analysis of published studies on the detection of extrathoracic metastases in patiënts presumed to have operable non-small cell lung cancer. Thorax 49:14-19,1994.
 
257 - Hirsch FR (2008)
Hirsch FR, Spreafico A, Novello S, et al. The prognostic and predictive role of histology in advanced non-small cell lung cancer: A literature review. J Thorac Oncol 3;1468-1481, 2008.
 
258 - Hirsch FR (2006)
Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non–small-cell lung cancer. J Clin Oncol 24:5034–5042, 2006.
 
259 - Hirsch FR (2007)
Hirsch FR, Varella-Garcia M, Cappuzzo F, et al. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patiënts treated with gefitinib. Ann Oncol 18:752-760, 2007.
 
260 - Hofmann HS (2002)
Hofmann HS, Taege C, Lautenschlager C, Neef H, Silber RE. Microscopic (R1) and macroscopic (R2) residual disease in patiënts with resected non-small cell lung cancer. Eur J Cardiothorac Surg 21:606-610, 2002.
 
261 - Holaday WJ (1974)
Holaday WJ, Assor D. Ten thousand consecutive frozen sections. A retrospective study focusing on accuracy and quality control. Am J Clin Pathol 61:769-777, 1974.
 
262 - Holtkamp C (2010)
Holtkamp C. et al. Guideline implementation for patiënts with non-small cell lung carcinoma (NSCLC) in the Netherlands. Towards improvements of quality of care. Abstract GIN, 2010.
 
263 - Holty JE (2005)
Holty JE, Kuschner WG, Gould MK. Accuracy of transbronchial needle aspiration for mediastinal staging of non-small cell lung cancer: a meta-analysis. Thorax ;60:949-955, 2005.
 
264 - Hopwood P (2000)
Hopwood P, Stevens RJ. Depression in patiënts with lung cancer: prevalence and risk factors derived from quality of life data. J Clin Oncol 18:893-903, 2000.
 
265 - Hotta K (2004)

Hotta K, Matsuo K, Ueoka H, et al: Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patiënts with advanced non-small-cell lung cancer. J Clin Oncol 22:3852-3859, 2004.

 
266 - Hout WB van den (2003)
Hout WB van den, Linden YM van der, Steenland E, Wiggenraad RG, Kievit J, Haes H de, et al. Single- versus multiplefraction radiotherapy in patiënts with painful bone metastases: cost-utility analysis based on a randomized trial. J Natl Cancer Inst 95:222-229, 2003.
 
267 - Huang J (2003)
Huang J, Barbera L, Brouwers M, Browman G, Mackillop WJ. Does delay in starting treatment affect the outcomes of radiotherapy? A systematic review. J Clin Oncol ;21:555-563, 2003.
 
268 - Icard P (1999)
Icard P, Regnard J, Guibert L, Magdeleinat P, Jaufffret B, Levasseur P. Survival and prognostic factors in patiënts undergoing parenchymal saving bronchoplastic operation for primary lung cancer: a series of 110 consecutive cases. Eur J Cardiothorac Surg 15:426-432,1999.
 
269 - Inoue A (2009)
Inoue A, Kobayashi K, Usui K, Maemondo M, et al. First-line gefitinib for patiënts with advanced Non–Small-Cell Lung Cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 27:1394-1400, 2009.
 
270 - Swensen SJ (1997)
Swensen SJ, Silverstein MD, Ilstrup DM, Schleck CD, Edell ES. The probability of malignancy in solitary pulmonary nodules. Application to small radiologically indeterminate nodules. Arch Intern Med 157:849-855, 1997.
 
271 - Melfi FM (2008)
Melfi FM, Lucchi M, Davini F, Viti A, Fontanini G, Boldrini L, Boni G, Mussi A.Intraoperative sentinel lymph node mapping in stage I non-small cell lung cancer: detection of micrometastases by polymerase chain reaction. Eur J Cardiothorac Surg 34:181-186, 2008.
 
272 - Italiano A (2009)
Italiano A, Cortot AB, Ilie M, et al. EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: implications for anti-EGFR treatment of a rare lung malignancy. Int J Cancer 125:2479-2482, 2009.
 
273 - Izbicki JR (1996)
Izbicki JR, Passlick B, Hosch SB, Kubuschock B, Schneider C, Busch C, et al. Mode of spread in the early phase of lymphatic metastasis in non-small-cell lung cancer: significance of nodal micrometastasis. J Thorac Cardiovasc Surg 112:623-630, 1996.
 
274 - Izbicki JR (1998)
Izbicki JR, Passlick B, Pantel K, Pichlmeier U, Hosch SB, Karg O, et al. Effectiveness of radical systematic mediastinal lymphadenectomy in patiënts with resectable non-small cell lung cancer: results of a prospective randomized trial. Ann Surg 227:138-144, 1998.
 
275 - Landreneau R (1997)
Landreneau R, Sugarbaker D, Mack M, Hazelrigge S, Luketich J, Fetterman L, et al. Wedge resection versus lobectomy for stage I (T1N0M0) non-small-cell lung cancer. J Thorac Cardiovasc Surg 113:691-700, 1997.
 
276 - Jackman DM (2007)
Jackman DM, Yeap BY, Lindeman NI, et al. Phase II clinical trial of chemotherapy-naive patiënts > or = 70 years of age treated with erlotinib for advanced non–small-cell lung cancer. J Clin Oncol 25:760-766, 2007.
 
277 - Jacox A (1994)
Jacox A, Carr DB, Payne R. New clinical-practice guidelines for the management of pain in patiënts with cancer. N Engl J Med 330: 651–655, 1994.
 
278 - Janssen-Heijnen ML (1998)
Janssen-Heijnen ML, Schipper RM, Razenberg PP, Crommelin MA, Coebergh JW. Prevalence of co-morbidity in lung cancer patiënts and its relationship with treatment: a population-based study. Lung Cancer 21:105-113, 1998.
 
279 - Jensen AR (2002)
Jensen AR, Mainz J, Overgaard J. Impact of delay on diagnosis and treatment of primary lung cancer. Acta Oncologica 41:146-152, 2002.
 
280 - Jensik RJ (1979)
Jensik RJ, Faber LP, Kittle CF. Segmental resection for bronchogenic carcinoma. Ann Thorac Surg 8:475-483, 1979.
 
281 - Jeremic B (2002)
Jeremic B, Classen J, Bamberg M. Radiotherapy alone in technically operable, medically inoperable, early-stage (I/II) non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 54:119-130, 2002.
 
282 - Jeremic B (1995)
Jeremic B, Shibamoto Y, Acimovic L, Djuric L. Randomized trial of hyperfractionated radiation therapy with or without concomitant chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol 13:452-458, 1995.
 
283 - Jeremic B (1996)
Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Hyperfractionated radiation therapy with or without concomitant low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study. J Clin Oncol 14:1065-1070, 1996.
 
284 - Jiang J (2007)

Jiang J, Liang X, Zhou X, et al: A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer. Lung Cancer 57:348-358, 2007.

 
285 - Johnson DH (2004)
Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase III trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced and metastastic non-small-cell lung cancer . J Clin Oncol 2004;22:2184-2191.
 
286 - Jones RV (1994)
Jones RV, Greenwood B. Breast cancer: causes of patiënt distress identified by qualitative analysis. Br J Gen Pract 44:370-371, 1994.
 
287 - Julian-Reynier C (1998)
Julian-Reynier C, Eisinger F, Chabal F, Aurran Y, Bignon YJ, Nogues C. Time elapsing from cancer diagnosis and anxiety in women attending cancer genetic clinics. Oncol Rep 5:885-888, 1998.
 
288 - Kaiser LR (1989)
Kaiser LR, Fleshner P, Keller S, Martini N. Significance of extramucosal residual tumor at the bronchial resection margin. Ann Thorac Surg 47:265-269, 1989.
 
289 - Kang JH (2003)
Kang JH, Kim KD, Chung KY. Prognostic value of visceral pleura invasion in non-small cell lung cancer. Eur J Cardiothorac Surg 23:865-869, 2003.
 
290 - Kao CH (2000)
Kao CH, Hsieh JF, Tsai SC, Ho YJ, Yen RF. Comparison and discrepancy of 18F-2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases. Anticancer Res 20:2189-2192, 2000.
 
291 - Kara M (2002)
Kara M, Dikmen E, Kilic D, Dizbay Sack S, Orhan D, Kenan Kose S, et al. Prognostic implications of microscopic proximal bronchial extension in non-small cell lung cancer. Ann Thorac Surg 74:348-54, 2002.
 
292 - Karnofsky DA (1948)
Karnofsky DA, Abelmann WH, Kraver LF, Burchernal JH. The use of nitrogen mustard in palliative treatment of carcinoma with particular reference to bronchogenic carcinoma. Cancer 1:634-669, 1948
 
293 - Kaufman Z (1986)
Kaufman Z, Lew S, Griffel B, Dinbar A. Frozen-section diagnosis in surgical pathology. A prospective analysis of 526 frozen sections. Cancer 57:377-379, 1986.
 
294 - Kawahara K (1994)
Kawahara K, Akamine S, Tsuji H, et al. Bronchoplastic procedures for lung cancer: clinical study in 136 patiënts. World J Surg 18:822-825, 1994.
 
295 - Kawano R (2002)
Kawano R, Hata E, Ikeda S, Sakaguchi H. Micrometastasis to lymph nodes in stage I left lung cancer patiënts. Ann Thorac Surg 73:1558-562, 2002.
 
296 - Kayser K (1993)
Kayser K, Anyanwu E, Bauer H-G, Vogt-Moykopf I. Tumor presence at the resection boundaries and lymph-node metastasis in bronchial carcinoma patiënts. Thorac Cardiovasc Surg 41:308-311, 1993.
 
297 - Kearney DJ (1994)
Kearney DJ. Assessment of operative risk in patiënts undergoing lung resection. Importance of predicted pulmonary function. Physiologic evaluation of pulmonary function in the candidate for lung resection. Chest 105:753-759, 1994.
 
298 - Keller SM (2002)
Keller SM. Complete mediastinal lymph node dissection-does it make a difference? Lung Cancer 2002;36:7-8, 2002
 
299 - Kelly RF (2004)
Kelly RF, Tran T, Holmstrom A, Murar J, Segurola RJ, Jr. Accuracy and cost-effectiveness of [18F]-2-fluoro-deoxy-D-glucose-positron emission tomography scan in potentially resectable non-small cell lung cancer. Chest 125:1413-1423, 2004.
 
300 - Kernstine KH (2003)
Kernstine KH. Positron emission tomography with 2-[18f]fluoro-2-deoxy-D-glucose: can it be used to accurately stage the mediastinum in non-small cell lung cancer as an alternative to mediastinoscopy? J Thorac Cardiovasc Surg 126:1700-1703, 2003.
 
301 - Khambata-Ford S (2010)
Khambata-Ford S, Harbison CT, Hart LL, et al. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 28:918-927, 2010.
 
302 - Khayyata S (2009)
Khayyata S, Yun S, Pasha T, et al. Value of P63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine-needle aspiration specimens. Diagn Cytopathol 37:178-183, 2009.
 
303 - Kim ES (2008)
Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial. Lancet 372:1809-1818, 2008.
 
304 - Kim ES (2008)
Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, Li LY, Watkins CL, Sellers MV, Lowe ES, Sun Y, Liao ML, Osterlind K, Reck M, Armour AA, Shepherd FA, Lippman SM, Douillard JY. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet. 372:1809-1818, 2008.
 
305 - Kim ST (2010)
Kim ST, Lee J, Kim JH, Won YW, Sun JM, Yun J, Park YH, Ahn JS, Park K, Ahn MJ. Comparison of gefitinib versus erlotinib in patiënts with nonsmall cell lung cancer who failed previous chemotherapy. Cancer 116:3025-3033, 2010.
 
306 - Kim YT (2005)
Kim YT, Sung SW, Kim JH. Local control of disease related to lymph node involvement in non-small cell lung cancer after ‘sleeve’-lobectomy compared with pneumonectomy. Ann Thorac Surg Apr 79: 1153 - 1161, 2005.
 
307 - Klepetko W (1999)
Klepetko W, Wisser W, Birsan T. T4 tumors with infiltration of the thoracic aorta: is an operation reasonable? Ann Thorac Surg 67:340-44, 1999.
 
308 - Koike T (2003)
Koike T, Yamato Y, Yoshiya K, Shimoyama T, Suzuki R. Intentional limited pulmonary resection for peripheral T1N0M0 small-sized lung cancer. J Thorac Cardiovasc Surg 125:924-928, 2003
 
309 - Komaki R (2000)
Komaki R, Roth JA, Walsh GL, Putnam JB, Vaporciyan A, Lee JS, et al. Outcome predictors for 143 patiënts with superior sulcus tumors treated by multidisciplinary approach at the University of Texas MD Anderson Cancer Center. Int J Radiat Oncol Biol Phys 48:347-354, 2000.
 
310 - Kondo H (1993)
Kondo H, Asamura H, Suemasu K, Goya T, Tsuciya R, Naruke T, et al. Prognostic significance of pleural lavage cytology immediately after thoracotomy in patiënts with lung cancer. J Thorac Cardiovasc Surg 106:1092-1097, 1993.
 
311 - Kramer GWPM (2005)
Kramer GWPM, Wanders SL, Noordijk EM, Vonk EJA, van Houwelingen HC, van den Hout WB, Geskus RB, Scholten M, Leer JWH. Results of the Dutch National Study of the Palliative Effect of Irradiation Using Two Different Treatment Schemes for Non–Small-Cell Lung Cancer. J Clin Oncol 5:2962-2970, 2005.
 
312 - Kramer H (2003)
Kramer H, Groen HJ. Current concepts in the mediastinal lymph node staging of non-small cell lung cancer. Ann Surg 238:180-188, 2003.
 
313 - Kvale PA (2003)
Kvale PA, Simoff M, Prakash UB. Palliative Care. Chest 123:S284S-311, 2003.
 
314 - Kwaliteit van kankerzorg in Nederland (2010)
Kwaliteit van kankerzorg in Nederland. Signaleringscommissie Kanker van KWF Kankerbestrijding KWF. VandenBoogaard Print& Mediamanagement, Oisterwijk, 55-66, 2010.
 
315 - Kwong KF (2005)

Kwong KF, Edelman MJ, Suntharalingam M, et al. High-dose radiotherapy in trimodality treatment of Pancoast tumors results in high pathologic complete response rates and excellent long-term survival. J Thorac Cardiovasc Surg 129:1250-1257, 2005

 
316 - Lacasse Y (1998)
Lacasse Y, Bucher HC, Wong E, Griffith L, Walter S, Ginsberg RJ, et al, for the Canadian Lung Oncology Group. ‘Incomplete resection’ in non-small cell lung cancer: need for a new definition. Ann Thorac Surg 65:220-226, 1998.
 
317 - Lagerwaard FJ (2008)
Lagerwaard FJ, Haasbeek CJA, Smit EF, Slotman BJ, Senan S. Outcomes of Risk-Adapted Fractionated Stereotactic Radiotherapy for Stage I Non–Small-Cell Lung Cancer. Int J Radiat Oncol Biol Phys 70:685-692, 2008.
 
318 - Lamont JP (2002)
Lamont JP, Kakuda JT, Smith D, Wagman LD, Grannis F-WJ. Systematic postoperative radiologic follow-up in patiënts with non-small cell lung cancer for detecting second primary lung cancer in stage IA. Arch Surg 137:935-938, 2002.
 
319 - Landreneau R (1997)
Landreneau R, Sugarbaker D, Mack M, Hazelrigge S, Luketich J, Fetterman L, et al. Wedge resection versus lobectomy for stage I (T1N0M0) non-small-cell lung cancer. J Thorac Cardiovasc Surg 113:691-700, 1997.
 
320 - Langer C (2010)
Langer C, Hirsch V. Skeletal morbidity in lung cancer patiënts with bone metastases: Demonstrating the need for early diagnosis and treatment with bisphosphonates. Lung Cancer 67: 4-11, 2010.
 
321 - Langer CJ (2008)
Langer CJ, O’Byrne KJ, Socinski MA, et al. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patiënts with chemotherapy-naive advanced non-small cell lung cancer. J Thorac Oncol 3:623-630, 2008.
 
322 - Larcos G (1996)
Larcos G, Maisey MN. FDG-PET screening for cerebral metastases in patiënts with suspected malignancy. Nucl Med Commun 17:197-198, 1996.
 
323 - Lardinois D (2003)
Lardinois D, Walter Weder W, Hany TF,Kamel EM, Korom S,Seifert B, von Schulthess GK, Steinert HC. Staging of Non–Small-Cell Lung Cancer with integrated positron-emission tomography and computed tomography. New Engl J Med 348:2500-2507, 2003.
 
324 - Larsen SS (2002)
Larsen SS, Krasnik M, Vilmann P, Jacobsen GK, Pedersen JH, Faurschou P, et al. Endoscopic ultrasound guided biopsy of mediastinal lesions has a major impact on patiënt management. Thorax 57:95-96, 2002
 
325 - LeChevalier T (2005)
LeChevalier T, Scagliotti G, Natale R, et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 2005;47:69-80.
 
326 - Lee YJ (2010)
Lee YJ, Cho BC, Jee SH, et al. Impact of environmental tobacco smoke on the incidence of mutations in epidermal growth factor receptor gene in never-smoker patiënts with non-small-cell lung cancer. J Clin Oncol 28:487-492, 2010.
 
327 - Lemaire A (2006)
Lemaire A, Nikolic I, Petersen T, Haney JC, Toloza EM, Harpole DH, Jr., et al. Nine-year single center experience with cervical mediastinoscopy: complications and false negative rate. Ann Thorac Surg ;82:1185-1189, 2006.
 
328 - Lequaglie C (2003)
Lequaglie C, Conti B, Brega Massone PP, Giudice G. Unsuspected residual disease at the resection margin after surgery for lung cancer: fate of patiënts after long-term follow-up. Eur J Cardiothorac Surg 23:229-232, 2003.
 
329 - Lerma B (2004)
Lerma B.S. et al. Med Clin 122; 281, 2004.
 
330 - Lesser T (1997)
Lesser T, Brenner A, Bartel M. [Recurrence after curative operation of non-small-cell bronchial carcinoma]. Zentralbl Chir 122:642-648, 1997.
 
331 - Leyn P de (1996)
Leyn P de, Schoonooghe P, Deneffe, G, Raemdonck D van, Coosemans W, Vansteenkiste J, et al. Surgery for nonsmall cell lung cancer with unsuspected metastasis to ipsilateral mediastinal or subcarinal nodes (N2 disease). Eur J Cardiothorac Surg ,10:649-54, discussion 654-655, 1996
 
332 - Liewald F (1992)
Liewald F, Hatz RA, Dienemann H, Sunder-Plassmann L. Importance of microscopic residual disease at the bronchial resection margin after resection for non-small cell carcinoma of the lung. J Thorac Cardiovasc Surg 104:408-412, 1992.
 
333 - Lilenbaum R (2008)
Lilenbaum R, Axelrod R, Thomas S, et al. Randomized phase II trial of erlotinib or standard chemotherapy in patiënts with advanced non–small cell lung cancer and a performance status of 2. J Clin Oncol 26:863-869, 2008.
 
334 - Lilenbaum R (2008)
Lilenbaum R, Axelrod R, Thomas S, et al. Randomized phase II trial of erlotinib or standard chemotherapy in patiënts with advanced non–small cell lung cancer and a performance status of 2. J Clin Oncol 26:863-869, 2008.
 
335 - Lilenbaum RC (2005)
Lilenbaum RC, Herndon JE 2nd, List MA, et.al. Single-agent versus combination chemotherapy in advanced non–small-cell lung cancer: The Cancer and Leukemia Group B (study 9730). J Clin Oncol 23:190-196, 2005.
 
336 - Linardou H (2009)
Linardou H, Dahabreh IJ, Bafaloukos D, Kosmidis P, Murray S. Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nature Reviews Clinical Oncology 6, 352-366, 2009.
 
337 - Linardou H (2008)
Linardou H, Dahabreh IJ, Kanaloupiti D, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 9:962-972, 2008.
 
338 - Linardou H (2008)
Linardou H, Dahabreh IJ, Kanaloupiti D, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. The Lancet Oncology, 9, 962 - 972, 2008.
 
339 - Joyce M (2008)
Joyce M. Supportive care in lung cancer. Semin Oncol Nurs. 2008 Feb;24(1):57-67.
 
340 - Linardou H (2008)
Linardou H, Dahabreh IJ, Kanaloupiti D, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. The Lancet Oncology, 9, 962 - 972, 2008.
 
341 - Liptay MJ (2002)
Liptay MJ, Grondin SC, Fry WA, Pozdol C, Carson D, Knop C, et al. Intraoperative sentinel lymph node mapping in non-small-cell lung cancer improves detection of lymph node metastases. J Clin Oncol 20:1984-988, 2002.
 
342 - Lipton A (2010)
Lipton A, Stopeck A, von Moos R et al. A meta-analysis of results from two randomized, double-blind studies of denosumab versus zoledronic acid (ZA) for treatment of bone metastases. ASCO MEETING abstracts 9015, 2010.
 
343 - Little AG (2002)
Little AG. Sentinel lymph node biopsy for staging of lung cancer. Surg Clin North Am 82:561-572, 2002.
 
344 - Lynch TJ (2010)
Lynch TJ, Patel T, Dreisbach L, et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non–small-cell lung cancer: Results of the randomized multicenter phase III trial BMS099. J Clin Oncol 2010; 28: 911-917.
 
345 - Macarenco RS (2008)
Macarenco RS, Uphoff TS, Gilmer HF, et al. Salivary gland-type lung carcinomas: an EGFR immunohistochemical, molecular genetic, and mutational analysis study. Mod Pathol 21:1168-1175, 2008.
 
346 - Mackillop WJ (1994)
Mackillop WJ, Fu H, Quirt CF, Dixon P, Brundage M, Yunzheng Zhou. Waiting for radiotherapy in Ontario. Int J Radiation Oncology Biol Phys 30:221-228, 1994.
 
347 - Maemondo M (2010)
Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, et al. Gefitinib or chemotherapy for Non–Small-Cell Lung Cancer with mutated EGFR. N Engl J Med 362:2380-2388, 2010.
 
348 - Magdeleinat P (2001)
Magdeleinat P, Alifano M, Benbrahem C, Spaggiari L, Porrello C, Puyo P, Levasseur P, Regnard J. Surgical treatment of lung cancer invading the chest wall: results and prognostic factors. Ann Thorac Surg 71:1094-1099, 2001.
 
349 - Maggi G (1990)
Maggi G, Casadio C, Manusco M, Oliaro A, Cianci R, Ruffini E. Resection and radical lymphadenectomy for lung cancer: prognostic significance of lymphatic metastases. Int Surg 75:17-21, 1990.
 
350 - Mair S (1991)
Mair S, Lash RH, Suskin D, Mendelsohn G. Intraoperative surgical specimen evaluation: frozen section analysis, cytologic examination, or both? A comparative study of 206 cases. Am J Clin Pathol 96:8-14, 1991.
 
351 - Manac'h D (2001)
Manac'h D, Riquet M, Medioni J, Le Pimpec-Barthes F, Dujon A, Danel C. Visceral pleura invasion by non-small cell lung cancer: an underrated bad prognostic factor. Ann Thorac Surg 71:1088-1093, 2001.
 
352 - Manser R (2005)
Manser R, Wright G, Hart D, Byrnes G, Campbell DA. Surgery for early stage non-small cell lung cancer. Cochrane Database Syst Rev 2005;(1):CD004699.
 
353 - Manser R (2005)
Manser R, Wright G, Hart D, Byrnes G, Campbell DA. Surgery for early stage non-small cell lung cancer. Cochrane Database Systemic Reviews 1:CD004699, 2005.
 
354 - Marcus PM (2000)
Marcus PM, Bergstralh EJ, Fagerstrom RM, Williams DE, Fontana R, Taylor WF, et al. Lung cancer mortality in the Mayo Lung Project: impact of extended follow-up. J Natl Cancer Inst 92:1308-1316, 2000.
 
355 - Marchevsky AM (2010)
Marchevsky AM, Gupta R, Kusuanco D, Mirocha J, McKenna RJ Jr. The presence of isolated tumor cells and micrometastases in the intrathoracic lymph nodes of patiënts with lung cancer is not associated with decreased survival. Hum Pathol.41:1536-1543, 2010.
 
356 - Marchevsky AM (2003)
Marchevsky AM, Qiao JH, Krajisnik S, Mirocha JM, Mckenna RJ. The prognostic significance of intranodal isolated tumor cells and micrometastases in patiënts with non-small cell carcinoma of the lung. J Thorac Cardiovasc Surg 126:551-557, 2003.
 
357 - Marino P (1995)
Marino P, Preatoni A, Cantoni A. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta-analysis. Cancer 76:593-601, 1995.
 
358 - Markos J (1989)
Markos J, Mullan BP, Hillman DR, Musk AW, Antico VF, Lovegrove FT, et al. Preoperative assessment as a predictor of mortality and morbidity after lung resection. Am Rev Respir Dis 139:902-910, 1989
 
359 - Martínez-Monge R (1994)
Martínez-Monge R, Herreros J, Aristu JJ, et al: Combined treatment in superior sulcus tumors. Am J Clin Oncol 17:317-322,1994.
 
360 - Martini N (1995)
Martini N, Bains MS, Burt ME, Zakowwski M, McCormack P, Rusch V, et al. Incidence of local recurrence in second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg 89:836-41, 1995.
 
361 - Martini N (1987)
Martini N, Flehinger BJ. The role of surgery in N2 lung cancer. Surg Clin North Am 67:1037-1049, 1987.
 
362 - Martini N (1994)
Martini N, Yellin A, Ginsberg RJ, Bains MS, Burt ME, McCormack PM, et al. Management of non-small cell lung cancer with direct mediastinal involvement. Ann Thorac Surg 58:1447-1451, 1994.
 
363 - Maruyama R (2000)
Maruyama R, Sugio K, Fukuyama Y, Hamatake M, Sakada T, Saitoh G, et al. Evaluation of p53 alterations in occult lymph node metastases. J Surg Oncol 73:143-147, 2000.
 
364 - Massard G (2000)
Massard G, Doddoli C, Gasser B, Ducrocq X, Kessler R, Schumacher C, et al. Prognostic implications of a positive bronchial resection margin. Eur J Cardiothorac Surg 17:557-565, 2000.
 
365 - Mathisen DJ (1991)
Mathisen DJ, Grillo HC. Carinal resection for bronchogenic carcinoma. J Thorac Cardiovasc Surg 102:16-22, 1991.
 
366 - Maurea S (1999)
Maurea S, Mainolfi C, Bazzicalupo L, Panico MR, Imparato C, Alfano B, et al. Imaging of adrenal tumors using FDG PET: comparison of benign and malignant lesions. Am J Roentgenol 173:25-9, 1999.
 
367 - Maygarden S (2004)
Maygarden S, Detterbeck FC, Funkhouser WK. Bronchial margins in lung cancer resection specimens: utility of frozen section and gross evaluation. Mod Pathol 1-7, 2004.
 
368 - Maziak DE (2009)
Maziak DE, Darling GE, Inculet RI, Gulenchyn KY, Driedger AA, Ung YC, Miller JD, Gu CS, Cline KJ, Evans WK, Levine MN. Positron emission tomography in staging early lung cancer: a randomized trial. Ann Intern Med 151:221-228, 2009.
 
369 - McCaughan (1985)
McCaughan, Martini N, Bains M, McCormack M. Chest wall invasion in carcinoma of the lung. J Thorac Cardiovasc Surg 89:836-841, 1985.
 
370 - Meerbeeck J van (1996)
Meerbeeck J van, Weyler J, Thibaut A, Vansteenkiste J, Aumann J, Deneffe G, et al. Second primary lung cancer in Flanders: frequency, clinical presentation, treatment and prognosis. Lung Cancer 15:281-295, 1996.
 
371 - Meerbeeck JP van (2002)
Meerbeeck JP van, Damhuis RA, Vos de Wael ML. High postoperative risk after pneumonectomy in elderly patiënts with right-sided lung cancer. Eur Respir J 19:141-5, 2002.
 
372 - Meester T de (1989)
Meester T de, Albertucci M, Dawson P, Montner S. Management of tumor adherent to the vertebral column. J Thorac Cardiovasc Surg ;97:373-378 1989.
 
373 - Melek H (2008)
Melek H, Gunluoglu MZ, Demir A, Akin H, Medetoglu B, Kara HV, et al. The role of positron emission tomography (PET) in mediastinal staging of non-small cell lung cancer. Tuberk Toraks 56:56-63, 2008.
 
374 - Meyer TJ (1995)
Meyer TJ, Mark MM. Effects of psychosocial interventions with adult cancer patiënts: a meta-analysis of rando missed experiments. Health psychology 14:101-108, 1995.
 
375 - Mezzetti M (2002)
Mezzetti M, Panigalli T, Giuliani L, Raveglia F, Giudice F lo, Meda S. Personal experience in lung cancer ‘sleeve’-lobectomy and ‘sleeve’-pneumonectomy. Ann Thorac Surg 73:1736-1739, 2002
 
376 - Micames CG (2007)
Micames CG, McCrory DC, Pavey DA, Jowell PS, Gress FG. Endoscopic ultrasound-guided fine-needle aspiration for non-small cell lung cancer staging: A systematic review and metaanalysis. Chest ;131:539-548, 2007.
 
377 - Mitsudomi T (2010)
Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, et al. Gefitinib versus cisplatin plus docetaxel in patiënts with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. The Lancet Oncology, 11, 121 - 128, 2010.
 
378 - Mizushima Y (1997)
Mizushima Y, Noto H, Kusajima Y, Yamashita R, Sugiyama S, Kashii T, Kobayashi M. Results of pneumonectomy for non-small cell lung cancer. Acta Oncol 36:493-497, 1997.
 
379 - Mok TS (2009)
Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957, 2009.
 
380 - Morice RC (1992)
Morice RC. Exercise testing in the evaluation of patiënts at high risk for complications from lung resection. Chest 101:356-361, 1992.
 
381 - Morinaga R (2007)
Morinaga R, Okamoto I, Furuta K, et al. Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation. Lung Cancer 58:411-413, 2007.
 
382 - Morita S (2009)
Morita S, Okamato I. Combined survival analysis of prospective clinical trials of gefinitib for non-small cell lung cancer with EGFR mutations. Clin Cancer Res 15:4493-4498, 2009.
 
383 - Mountain CF (1986)
Mountain CF. A new international staging system for lung cancer.Chest 89(Suppl):S225-33, 1986.
 
384 - Mountain CF (1997)
Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 111:1710-1717, 1997.
 
385 - Nagata Y (2005)
Nagata Y, Takayama K, Matsuo Y, et al. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys 63:1427-1431, 2005.
 
386 - Nakahara K (1988)
Nakahara K, Ohno K, Hashimoto J, Miyoshi S, Maeda H, Matsumura A, et al. Prediction of postoperative respiratory failure in patiënts undergoing lung resection for lung cancer. Ann Thorac Surg 46:549-552, 1988.
 
387 - Nakazawa H (1968)
Nakazawa H, Rosen P, Lane N, Lattes R. Frozen section experience in 3000 cases. Accuracy, limitations, and value in residency training. Am J Clin Pathol 49:41-51, 1968.
 
388 - Naruke T (1999)
Naruke T, Tsuchiya R, Kondo H, Nakayama H, Asamura H. Lymph node sampling: how should it be done? Eur J Cardio-thorac Surg 16(Suppl 1):S17-24, 1999.
 
389 - Nashef SA (1993)
Nashef SA, Kakadellis JG, Hasleton PS, Whittaker JS, Gregory CM, Jones MT. Histological examination of preoperative frozen sections in suspected lung cancer. Thorax 48:388-389, 1993.
 
390 - Naunheim KS (1994)
Naunheim KS, Kesler KA, D’Orazio SA, Fiore AC, Judd DR. Lung cancer surgery in the octogenarian. Eur J Cardiothorac Surg 8:453-456, 1994.
 
391 - Nederlandse Werkgroep Hoofd-Hals Tumoren NWHHT (2003)
Nederlandse Werkgroep Hoofd-Hals Tumoren NWHHT (2003). Richtlijn Mondholte/Oropharynxcarcinoom (concept).
 
392 - Nicholson A (2010)
Nicholson A, Gonzalez D, Shah P, et al. Refining the Diagnosis and EGFR Status of Non-small Cell Lung Carcinoma in Biopsy and Cytologic Material, Using a Panel of Mucin Staining, TTF-1, Cytokeratin 5/6, and P63, and EGFR Mutation Analysis. J Thorac Oncol 5:436-41, 2010.
 
393 - Nicholson AG (1997)
Nicholson AG, Graham AN, Pezzella F, Agneta G, Goldstraw P, Pastorino U. Does the use of immunohistochemistry to identify micrometastases provide useful information in the staging of node-negative non-small cell lung carcinomas? Lung Cancer 18:231-40, 1997.
 
394 - Nohl-Ohser HC (1983)
Nohl-Ohser HC. Lymphatics of the lung. In: Shields TW (ed). General Thoracic Surgery. 2nd edition. Philadelphia: Lea and Febiger, 72-81, 1983.
 
395 - Non-Small Cell Lung Cancer Collaborative Group NSCLCCG (2010)
Non-Small Cell Lung Cancer Collaborative Group NSCLCCG. Chemotherapy and supportive care versus supportive care alone for advanced non-small cell lung cancer. Cochrane Database of Systematic Reviews 5:CD007309, 2010.
 
396 - Nosotti M (2005)
Nosotti M, Falleni M, Palleschi A, Pellegrini C, Alessi F, Bosari S, Santambrogio L. Quantitative real-time polymerase chain reaction detection of lymph node lung cancer micrometastasis using carcinoembryonic antigen marker. Chest 128:1539-1544, 2005.
 
397 - Inoue A (2009)
Inoue A, Kobayashi K, Usui K, Maemondo M, et al. First-line gefitinib for patiënts with advanced Non–Small-Cell Lung Cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 27:1394-1400, 2009.
 
398 - NSCLC Collaborative Group (1995)
NSCLC Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patiënts from 52 randomised clinical trials. BMJ 311:899-909, 1995.
 
400 - NSCLC Meta-Analyses Collaborate Group (2008)
NSCLC Meta-Analyses Collaborate Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patiënt data from 16 randomized controlled trials. J Clin Oncol 26:4617-4625, 2008.
 
401 - NSCLC Meta-analyses Collaborative Group (2010)
NSCLC Meta-analyses Collaborative Group, Arriagada R, Auperin A, Burdett S, Higgins JP, Johnson DH, Le Chevalier T, Le Pechoux C, Parmar MK, Pignon JP, Souhami RL, Stephens RJ, Stewart LA, Tierney JF, Tribodet H, van Meerbeeck J. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patiënt data. Lancet 375:1267-1277, 2010.
 
402 - Nyman J (2006)
Nyman J, Johansson KA, Hultén U. Stereotactic hypofractionated radiotherapy for stage I non-small cell lung cancer--mature results for medically inoperable patiënts. Lung Cancer 51:97-103, 2006.
 
403 - O`Rourke N (2000)
O`Rourke N, Edwards R. Lung cancer treatment waiting times and tumour growth. Clin Oncol (R Coll Radiol) 12:141-144., 2000.
 
404 - Ohkubo T (2000)
Ohkubo T, Okayasu T, Hashimoto M, Shiiya N, Konishi K, Motohara T, et al. [Surgery for intrathoracic recurrence of non-small cell lung cancer]. Kyobu Geka 53:127-131, 2000.
 
405 - Ohno Y (2008)
Ohno Y, Koyama H, Onishi Y, Takenaka D, Nogami M, Yoshikawa T, Matsumoto S, Kotani Y, Sugimura K. Non-small cell lung cancer: whole-body MR examination for M-stage assessment--utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT. Radiology. 2008 248:643-654, 2008.
 
406 - Okada M (2003)
Okada M, Sakamoto T, Nishio W, Uchino K, Tsuboshima K, Tsubota N. Pleural lavage cytology in non-small cell lung cancer: Lessons from 1000 consecutive resections. J Thorac Cardiovasc Surg 126:1911-1915, 2003.
 
407 - Okada M (1999)
Okada M, Tsubota N, Yoshimura M, Miyamoto Y, Matsuoka H. How should interlobar pleural invasion be classified? Prognosis of resected T3 non-small cell lung cancer. Ann Thorac Surg 68:2049-2052, 1999.
 
408 - Okada M (1998)
Okada M, Tsubota N, Yoshimura M, Miyamoto Y. Proposal for reasonable mediastinal lymphadenectomy in bronchogenic carcinomas: role of subcarinal nodes in selective dissection. J Thorac Cardiovasc Surg 116:949-953, 1998.
 
409 - Okada M (2000)
Okada M, Yamagishi H, Satake S, Matsuoka H, Miyamoto Y, Yoshimura M, et al. Survival related to lymph node involvement in lung cancer after ‘sleeve’-lobectomy compared with pneumonectomy. J Thorac Cardiovasc Surg 119:814-819, 2000.
 
410 - Okamoto I (2006)
Okamoto I, Araki J, Suto R, Shimada M, Nakagawa K, Fukuoka M. EGFR mutation in gefitinib-responsive small-cell lung cancer. Ann Oncol 17:1028-1029, 2006.
 
411 - Okumura M (1991)
Okumura M, Ohshima S, Kotake Y, Morino H, Kikui M, Yasumitsi T. Intraoperative pleural lavage cytology in lung cancer patiënts. Ann Thorac Surg 51:599-604, 1991.
 
412 - Older P (1993)
Older P. Preoperative evaluation of cardiac failure and ischemia in elderly patiënts by cardiopulmonary exercise testing. Chest 104:701-704, 1993
 
413 - Oneson RH (1989)
Oneson RH, Minke JA, Silverberg SG. Intraoperative pathologic consultation. An audit of 1,000 recent consecutive cases. Am J Surg Pathol 13:237-243, 1989.
 
414 - Onishi H (2007)
Onishi H, Shirato H, Nagata Y, et al. Hypofractionated Stereotactic Radiotherapy (HypoFXSRT) for Stage I Non-small Cell Lung Cancer: Updated Results of 257 Patiënts in a Japanese Multi-institutional Study. J Thorac Oncol 2:s94-s100, 2007.
 
415 - Oosterhuis JW (2001)
Oosterhuis JW, Theunissen PH, Bollen EC. Improved pre-operative mediastinal staging in non-small-cell lung cancer by serial sectioning and immunohistochemical staining of lymph-node biopsies. Eur J Cardiothorac Surg 20:335-338, 2001.
 
416 - O`Rourke N (2000)
O`Rourke N, Edwards R. Lung cancer treatment waiting times and tumour growth. Clin Oncol (R Coll Radiol) 12:141-144, 2000.
 
417 - Osaki T (2002)
Osaki T, Oyama T, Gu C-D, Yamashita T, So T, Takenoyama M, Sugio K, Yasumoto K. Prognostic Impact of Micrometastatic Tumor Cells in the Lymph Nodes and Bone Marrow of Patiënts With Completely Resected Stage I Non–Small-Cell Lung Cancer. J Clin Oncol 20:2930-2936, 2002.
 
418 - Page A (1987)
Page A, Nakhle G, Mercier C, Verdant A, Page P, Dontigny L, et al. Surgical treatment of bronchogenic carcinoma: the importance of staging in evaluating late survival. Can J Surg 30:96-99, 1987.
 
419 - Pagni S (1997)
Pagni S, Frederico JA, Ponn RB. Pulmonary resection for lung cancer in octogenarians. Ann Thorac Surg 63:785-789, 1997.
 
420 - Pallis AG (2008)
Pallis AG, Polyzos A, Boukovinas I, et al. Pooled analysis of elderly patiënts with non-small cell lung cancer treated with front line docetaxel/gemcitabine regimen: The Hellenic Oncology Research Group experience. J Thorac Oncol 3:505-510, 2008.
 
421 - Palma D (2010)
Palma D, Visser O, Lagerwaard FJ, Belderbos J, Slotman BJ, Senan S. Impact of introducing stereotactic lung radiotherapy for elderly patiënts with stage I non–small-cell lung cancer: A population-based time-trend analysis. J Clin Oncol 28:5153-5159; 2010.
 
422 - Park JO (2007)
Park JO, Kim SW, Ahn JS, et al: Phase III trial of two versus four additional cycles in patiënts who are nonprogressive after two cycles of platinum based chemotherapy in non–small-cell lung cancer. J Clin Oncol 25:5233-5239, 2007.
 
423 - Park S (2009)
Park S, Holmes-Tisch AJ, Cho EY, et al. Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer. J. Thorac. Oncol 4:809-815, 2009.
 
424 - Park SH (2009)
Park SH, Ha SY, Lee JI, et al. Epidermal growth factor receptor mutations and the clinical outcome in male smokers with squamous cell carcinoma of lung. J. Korean Med. Sci 24:448-452, 2009.
 
425 - Passlick B (2001)
Passlick B, Sitar I, Sienel W, Thetter O, Morresi-Hauf A. Significance of lymphangiosis carcinomatosa at the bronchial resection margin in patiënts with non-small cell lung cancer. Ann Thorac Surg 72:1160-1164, 2001.
 
426 - Pastorino U (1991)
Pastorino U, Valente M, Bedini V, Infante M, Tavecchio L, Ravasi G. Limited resection for stage I lung cancer. Eur J Surg 17:42-46, 1991.
 
427 - Patchell RA (2005)
Patchell RA, Tibbs PhA, Regine WF, et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. The Lancet, 366;643-648, 2005.
 
428 - Wahidi MM (2007)
Wahidi MM, Govert JA, Goudar RK, Gould MK, McCrory DC. Evidence for the treatment of patiënts with pulmonary nodules: when is it lung cancer? ACCP Evidence-Based Clinical Practice Guidelines (2nd edition). Chest 132:94S-107S, 2007.
 
429 - Pearman T (2008)
Pearman T. Psychosocial factors in lung cancer: Quality of life, economic impact, and survivorship implications. J of Psychosocial Oncol 2008, vol 26(1) 69-80.
 
430 - Pesek M (2009)
Pesek M, Benesova L, Belsanova B, Mukensnabl P, Bruha F, Minarik M. Dominance of EGFR and insignificant KRAS mutations in prediction of tyrosine-kinase therapy for NSCLC patiënts stratified by tumor subtype and smoking status. Anticancer Res 29:2767-2773, 2009.
 
431 - Pfister DG (2003)
Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, et al. Treatment of unresectable non-small-cell lung cancer. American Society of Clinical Oncology Guideline; update 2003. J Clin Oncol 22:1-24, 2004.
 
432 - Piccirillo JF (2000)
Piccirillo JF. Importance of comorbidity in head and neck cancer. Laryngoscope 110:593-602, 2000.
 
433 - Pierce RJ (1994)
Pierce RJ, Copland JM, Sharpe K, Barter CE. Preoperative risk evaluation for lung cancer resection: Predicted postoperative product as a predictor of surgical mortality. Am J Respir Crit Care Med 150:947-955, 1994.
 
434 - Pieterman RM (2000)
Pieterman RM, John W.G. van Putten JWG, Meuzelaar JJ, Mooyaart EL, Vaalburg W, Koëter GH, Fidler V, Pruim J, Groen HJM. Preoperative Staging of non–small-cell lung cancer with positron-emission tomography. N Engl J Med 343:254-261, 2000.
 
435 - Pieterman RM (2000)
Pieterman RM, van Putten JWG, Meuzelaar JJ, et al. Preoperative staging of non–small-cell lung cancer with positron-emission tomography. N Engl J Med 2000;343:254-261, 2000.
 
436 - Pignon (2008)
Pignon, J-P, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group. J Clin Oncol 26,3552-3559, 2008.
 
437 - Pirker R (2009)
Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patiënt with advanced non–small-cell lung cancer (FLEX): An open-label randomized phase III trial. Lancet 373:1525–1531, 2009.
 
438 - Pitz C (2003)
Pitz C, Brutel de la Riviere A, Swieten H van, Westermann C, Lammers JW, Bosch J van den. Results of surgical treatment of T4 non-small cell lung cancer. Eur J Cardiothorac Surg 24:1013-1018, 2003.
 
439 - Pitz CC (1996)
Pitz CC, Brutel de la Riviere A, Elbers H, Westermann C, Bosch J van den. Surgical treatment of 125 patiënts with non-small cell lung cancer and chest wall involvement. Thorax 51:846-850, 1996.
 
440 - Postmus (2007)
Postmus, Pieter E.; Brambilla, Elisabeth; Chansky, Kari; Crowley, John; Goldstraw, Peter; Patz, Edward F. Jr; Yokomise, Hiroyasu; on behalf of the International Association for the Study of Lung Cancer International Staging Committee,a Cancer Research and Biostatistics,b Observer.The IASLC Lung Cancer Staging Project: Proposals for Revision of the M Descriptors in the Forthcoming (Seventh) Edition of the TNM Classification of Lung Cancer. J Thor Oncol 2(8):686-693, 2007.
 
441 - Pozo-Rodriguez F (2005)
Pozo-Rodriguez F, Martin de Nicolas JL, Sanchez-Nistal MA, Maldonado A, Garcia de BS, Calero-Garcia R, et al. Accuracy of helical computed tomography and [18F] fluorodeoxyglucose positron emission tomography for identifying lymph node mediastinal metastases in potentially resectable non-small-cell lung cancer. J Clin Oncol 23:8348-8356, 2005.
 
442 - Wahidi MM (2007)
Wahidi MM, Govert JA, Goudar RK, Gould MK, McCrory DC. Evidence for the treatment of patiënts with pulmonary nodules: when is it lung cancer? ACCP Evidence-Based Clinical Practice Guidelines (2nd edition). Chest 132:94S-107S, 2007.
 
443 - Practice guidelines for cancer pain management (1996)
Practice guidelines for cancer pain management. A report by the American Society of Anesthesiologists Task Force on Pain Management, Cancer Pain Section. Anesthesiology 84:1243-1257, 1996.
 
444 - Pritchard RS (1996)
Pritchard RS, Anthony SP. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. A meta-analysis. Ann Intern Med 125:723-29, 1996.
 
445 - Puhakka HJ (1989)
Puhakka HJ. Complications of mediastinoscopy. J Laryngol Otol 103:312-315, 1989
 
446 - Quoix EA (2010)
, Oster J, Pichon E et al. Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patiënts aged 70 to 89: IFCT-0501 randomized phase III study in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2010; 28(15S):5s (abstract 2).
 
447 - Rajeswaran A (2008)
Rajeswaran A, Trojan A, Burnand B, et al. Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials. Lung Cancer 59:1-11, 2008.
 
448 - Rami-Porta (2007)
Rami-Porta, Ramón; Ball, David; Crowley, John; Giroux, Dorothy J.; Jett, James; Travis, William D.; Tsuboi, Masahiro; Vallières, Eric; Goldstraw, Peter; on behalf of the International Staging Committee. The IASLC Lung Cancer Staging Project: Proposals for the Revision of the T Descriptors in the Forthcoming (Seventh) Edition of the TNM Classification for Lung Cancer. J Thor Oncol 2(7):593-602, 2007.
 
449 - Ramlou R (2006)
Ramlou R, Gervais R, Krzakowski M, et al. Phase III study comparing oral topotecan to intravenous docetaxel in patiënts with pretreated advanced non-small-cell lung cancer. J Clin Oncol 24:2800-2807,2006.
 
450 - Rapoport Y (1993)
Rapoport Y, Kretler S, Chaitchik S, Algor R, K. Wiessler K. Psychosocial problems in head-and-neck cancer patiënts and their change with time since diagnosis. Ann Oncol 4:69-73, 1993.
 
451 - Ratto G (1991)
Ratto G, Piacenza G, Musante F, Serrano I, Giua R, Salio M, et al. Chest wall involvement by lung cancer: Computed tomographic detection and results of operation. Ann Thorac Surg 51:182-188, 1991
 
452 - Read R (1993)
Read R, Ziomek S, Ranval T, Eidt J, Gocio J, Schaefer R. Pulmonary artery ‘sleeve’-resection for abutting left upper lobe lesions. Ann Thorac Surg 55:850-854, 1993.
 
453 - Reck M (2009)
Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for non-squamous non-small-cell lung cancer: AVAIL. J Clin Oncol 2009;27:1227-1234.
 
454 - Reed CE (2003)
Reed CE, Harpole DH, Posther KE, Woolson SL, Downey RJ, Meyers BF, et al. Results of the American College of Surgeons Oncology Group Z0050 trial: The utility of positron emission tomography in staging potentially operable non-small cell lung cancer. JThorac Cardiovasc Surg 126:1943-1951, 2003.
 
455 - Rena O (2007)
Rena O, Carsana L, Cristina S, Papalia E, Massera F, Errico L, Bozzola C, Casadio C. Lymph node isolated tumor cells and micrometastases in pathological stage I non-small cell lung cancer: prognostic significance. Eur J Cardiothorac Surg 32:863-867, 2007.
 
456 - Rendina E (1999)
Rendina E, Venuta F, Giacomo T de, Ciccone AM, Moretti M, Ruvolo G, et al. ‘sleeve’-resection and prosthetic reconstruction of the pulmonary artery for lung cancer. Ann Thorac Surg 68:995-1002, 1999.
 
457 - Rickman OB (2009)
Rickman OB, Vohra PK, Sanyal B, et al. Analysis of ErbB receptors in pulmonary carcinoid tumors. Clin Cancer Res 15:3315-3324, 2009.
 
458 - Richtlijn behandeling van tabaksverslaving (2004)
Richtlijn behandeling van tabaksverslaving, CBO, 2004, http://www.stivoro.nl/Voor_professionals/Setting/Zorg/Richtlijn_Behandeling_van_tabaksverslaving/Default.aspx
 
459 - Richtlijn Herstel na Kanker (2010)
Richtlijn Herstel na Kanker, 2010, http://www.oncoline.nl/
 
460 - Richtlijn spirituele zorg (2010)
Richtlijn spirituele zorg, http://www.oncoline.nl/ 2010
 
461 - Riely GJ (2007)
Riely GJ, Kris M, Zhao B, et al. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patiënts with acquired resistance to erlotinib or gefitinib followed by addition of everolimus. Clin Cancer Res 13:5150-5155, 2007.
 
462 - Rintoul RC (2005)
Rintoul RC, Skwarski KM, Murchison JT, Wallace WA, Walker WS, Penman ID. Endobronchial and endoscopic ultrasound-guided real-time fine-needle aspiration for mediastinal staging. Eur Respir J ;25:416-421, 2005.
 
463 - Riquet M (2000)
Riquet M, Porte H, Chapelier A, Brichon PY, Bernard A, Dujon A, et al. Resection of lung cancer invading the diafragm. J Thorac Cardiovasc Surg 2000;120:417-418, 2000
 
464 - Risberg T (1996)
Risberg T, Sorbye SW, Norum J, Wist EA. Diagnostic delay causes more psychological distress in female than in male breast cancer patiënts. Anticancer Res 16:995-999, 1996.
 
465 - Robinson LA (2003)
Robinson LA, Wagner H, Ruckdeschel JC. Treatment of stage III non-small cell lung cancer. Chest 123:S202-220, 2003.
 
466 - Rocco G (1999)
Rocco G, Rendina E, Meroni A, Venuta F, Della Pona C, Giacomo T de, et al. Prognostic factors after surgical treatment of lung cancer invading the diafragm. Ann Thorac Surg 68:2065-2068, 1999.
 
467 - Roohan PJ (1998)
Roohan PJ, Bickell NA, Baptiste MS, Therriault GD, Ferrara EP, Siu AL. Hospital volume differences and five-year survival from breast cancer. Am J Public Health 88:454-457, 1998.
 
468 - Rosell R (2010)
Rosell R, Viteri S, Molina MA, Benlloch S, Taron M. Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer. Curr Opin Oncol 22:112-120, 2010.
 
469 - Rosen LS (2004)
Rosen LS, Gordon D, Tchekmedyian NS , Yanagihara R, Hirsh V, Krzakowski M, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patiënts with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase II , double-blind, placebo-controlled trial. Cancer 100:2613-2621, 2004.
 
470 - Rosen LS (2003)
Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patiënts with lung cancer and other solid tumors: a phase II , double-blind, randomized trial--the Zoledronic Acid Lung C ancer and Other Solid Tumors Study Group. J Clin Oncol 21:3150-3157, 2003.
 
471 - Ross JR (2003)
Ross JR, Saunders Y, Edmonds PM, Patel S, Broadley KE, Johnston SR. Systematic review on the role of bisphosphanates in skeletal morbidity in metastatic cancer. BMJ 327:469, 2003.
 
472 - Rossi G (2009)
Rossi G, Sartori G, Cavazza A, Tamberi S. Mucoepidermoid carcinoma of the lung, response to EGFR inhibitors, EGFR and K-RAS mutations, and differential diagnosis. Lung Cancer 63:159-160, 2009.
 
473 - Roswit B (1968)
Roswit B, Patno ME, Rapp R, Veinbergs A, Feder B, Stuhlbarg, et al. The survival of patiënts with inoperable lung cancer: A large scale randomized study of radiation therapy versus placebo. Radiology 90:688-697, 1968.
 
474 - Roviaro G (2001)
Roviaro G, Varoli F, Romanelli A, Vergani C, Maciocco M. Complications of tracheal ‘sleeve’-pneumonectomy: personal experience and overview of the literature. J Thorac Cardiovasc Surg ;121:234-240, 2001.
 
475 - Rowell NP (2004)
Rowell NP, O'Rourke NP. Concomitant chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev 2004; CD002140.
 
476 - Rusch V (2007)
Rusch V, Giroux DJ, Kraut MJ, et al. Induction Chemoradiation and Surgical Resection for Superior Sulcus Non–Small-Cell Lung Carcinomas: Long-Term Results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160) J Clin Oncol 25:313-318, 2007.
 
477 - Kwong KF (2005)
Kwong KF, Edelman MJ, Suntharalingam M, et al. High-dose radiotherapy in trimodality treatment of Pancoast tumors results in high pathologic complete response rates and excellent long-term survival. J Thorac Cardiovasc Surg 129:1250-1257, 2005
 
478 - Rusch (2009)
Rusch, Valerie W.; Asamura, Hisao; Watanabe, Hirokazu; Giroux, Dorothy J.; Rami-Porta, Ramon; Goldstraw, Peter; on Behalf of the Members of the IASLC Staging Committee The IASLC Lung Cancer Staging Project: A Proposal for a New International Lymph Node Map in the Forthcoming Seventh Edition of the TNM Classification for Lung Cancer. J Thor Oncol 4(5):568-577, 2009.
 
479 - Rusch (2007)
Rusch, Valerie W.; Crowley, John; Giroux, Dorothy J.; Goldstraw, Peter; Im, Jung-Gi; Tsuboi, Masahiro; Tsuchiya, Ryosuke; Vansteenkiste, Johan; on behalf of the International Staging Committee. The IASLC Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming Seventh Edition of the TNM Classification for Lung Cancer. J Thor Oncol 2(7):603-612, 2007.
 
480 - Rusthoven KE (2010)
Rusthoven KE, Pugh TJ. Stereotactic Body Radiation Therapy for Inoperable Lung Cancer. JAMA 303:2354-2355,2010.
 
481 - Ryan LS (1996)
Ryan LS. Psychosocial issues and lung cancer: A behavioral approach. Seminars in Oncology Nursing 1996, 318-323.
 
482 - Sadeghi A (1988)
Sadeghi A, Payne D, Rubinstein L, Lad T. Combined modality treatment for resected advanced non-small cell lung cancer: local control and local recurrence. Int J Radiat Oncol Biol Phys 15:89-97, 1988.
 
483 - Saintigny P (2005)
Saintigny P, Coulon S, Kambouchner M, Ricci S, Martinot E, Danel C, Breau JL, Bernaudin JF. Real-time RT-PCR detection of CK19, CK7 and MUC1 mRNA for diagnosis of lymph node micrometastases in non small cell lung carcinoma. Int J Cancer 115:777-782, 2005.
 
484 - Salvatierra A (1990)
Salvatierra A, Baamonde C, Llamas JM, Cruz F, Lopez-Pujol J. Extrathoracic staging of bronchogenic carcinoma. Chest 97:1052-1058, 1990.
 
485 - Sandler A (2006)
Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550, 2006.
 
486 - Sandler A (2010)
Sandler A, Yi J, Dahlberg S, Kolb MM, Wang L, Hambleton J, Schiller J, Johnson DH. Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer. J Thorac Oncol 9:1416-1423, 2010.
 
487 - Sarna L (2005)
Sarna L, Brown JK, Cooly ME, Williams RD, Chernecky C, Padilla G, Danao LL . Quality of life and meaning of illness of women with lung cancer. Oncology Nursing Forum 2005, vol 32 no1, 9-19.
 
488 - Sarna L (1998)
Sarna L. Lung cancer. In: Holland JC (ed). Psycho-Oncology. New York: Oxford University Press, 340-348, 1998.
 
489 - Saunders M (1997)
Saunders M, Dische S, Barret A, Harvey A, Gibson D, Parmar M. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: A randomised multicenter trial. Lancet 1997;350:161-165, 1997.
 
490 - Sause W (2000)

Sause W, Kolesar P, Taylor S, Johnson D. Final results of phase III trial in regionally advanced unresectable nonsmall cell lung cancer: Radiation Therapy Oncology group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 117:358-364, 2000.

 
491 - Sause W (2000)
Sause W, Kolesar P, Taylor S, Johnson D. Final results of phase III trial in regionally advanced unresectable nonsmall cell lung cancer: Radiation Therapy Oncology group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 117:358-364, 2000.
 
492 - Sause WT (2000)
Sause WT, Byhardt RW, Curran WJ, Fuller D, Graham MV, Ko B, et al. Follow-up of non-small cell lung cancer. ACR Appropriateness Criteria. Radiol 215(Suppl):1363-1372, 2000.
 
493 - Scagliotti GV (2003)
Scagliotti GV, Fossati R, Torri V, et al. For the Adjuvant Lung Project Italy/European Organisation for Research Treatment of Cancer–Lung Cancer Cooperative Group Investigators. Randomized Study of Adjuvant Chemotherapy for Completely Resected Stage I, II, or IIIA Non–Small-Cell Lung Cancer. J Nat Cancer Inst 95,1453-1461, 2003.
 
494 - Scagliotti GV (2008)
Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy naive patiënts with advanced-stage non–small-cell lung cancer. J Clin Oncol 26:3543-3551, 2008.
 
495 - Scagliotti GV (2008)
Scagliotti GV. et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patiënts with advanced-stage non-small cell lung cancer. J Clin Oncol 26; 3543-3551;2008.
 
496 - Schaake-Koning C (1992)
Schaake-Koning C, Bogaert W van den, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326: 524-530, 1992.
 
497 - Schaake-Koning C (1992)
Schaake-Koning C, Bogaert W van den, Dalesio O, Festen J, Hoogenhout J, Houtte P van, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med 326:524-530, 1992.
 
498 - Schil P van (1996)
Schil P van, Riviere A, Knaepen P, Swieten H, Reher S, Goossens D, et al. Long-term survival after bronchial ‘sleeve’-resection: univariate en multivariate analyses. Ann Thorac Surg 61:1087-1091, 1996.
 
499 - Schrameijer F (1992)
Schrameijer F, Brunenberg W. Psychosociale zorg bijkanker. Patiënten en hulpverleners over problemen en hulpaanbod. NcGv-reeks: 92-22. Utrecht: Nederlands centrum Geestelijke Volksgezondheid,1992
 
500 - Schwegler N (1997)
Schwegler N. Lungenkrebs-Hoffnungslosigkeit bei Inoperabilitat? 10 Jahre danach. Strahlenther Onkol 173:352-361, 1997.
 
501 - Scottish Cancer Therapy Network. Lung cancer (1998)
Scottish Cancer Therapy Network. Lung cancer. Edinburgh: Scottish Intercollegiate Guidelines Network, 1998
 
502 - Scucchi LF (1997)
Scucchi LF, Stefano D di, Cosentino L, Vecchione A. Value of cytology as an adjunctive intraoperative diagnostic method. An audit of 2,250 consecutive cases. Acta Cytol 41:1489-496, 1997.
 
503 - Sculier JP (2008)
Sculier JP, Chansky K; Crowley JJ, Van Meerbeeck J, Goldstraw P on behalf of the International Staging Committee and Participating Institutions. The Impact of Additional Prognostic Factors on Survival and their Relationship with the Anatomical Extent of Disease Expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the Proposals for the 7th Edition. J Thor Oncol 3(5):457-466, 2008.
 
504 - Segawa Y (2010)
Segawa Y, Kiura K, Takigawa N, et al. Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concomitant thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007. J Clin Oncol 28:3299-3306, 2010.
 
505 - Sequist LV (2008)
Sequist LV. First-generation epidermal growth factor receptor tyrosine kinase inhibitors in EGFR mutation: positive non-small cell lung cancer patiënts. J Thorac Oncol 3(6 Suppl 2):S143-145, 2008.
 
506 - Shah S (1995)
Shah S, Goldstraw P. Combined pulmonary and thoracic wall resection for stage III lung cancer. Thorax 50:782-784, 1995.
 
507 - Shell JA (2008)
Shell JA, Carolan M, Zhang Y, Meneses KD. The longitudinal effects of cancer treatment on sexuality in individuals with lung cancer. Oncology Nursing 2008, vol 35, no1, 73-79..
 
508 - Shepherd FA (2005)
Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005.
 
509 - Shepherd (2007)
Shepherd, Frances A.; Crowley, John; Van Houtte, Paul; Postmus, Pieter E.; Carney, Desmond; Chansky, Kari; Shaikh, Zeba; Goldstraw, Peter; on behalf of the International Association for the Study of Lung Cancer International Staging Committee and Participating Institutions. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals Regarding the Clinical Staging of Small Cell Lung Cancer in the Forthcoming (Seventh) Edition of the Tumor, Node, Metastasis Classification for Lung Cancer. J Thor Oncol 2(12):1067-1077, 2007.
 
510 - Shields TW (1972)
Shields TW. Preoperative radiation therapy in the treatment of bronchial carcinoma. Cancer 30:1388-1394, 1972.
 
511 - Shigematsu H (2005)
Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97:339-346, 2005.
 
512 - Shimizu K (2005)
Shimizu K, Yoshida J, Nagai K, Nishimura M, Ishii G, Morishita Y, et al. Visceral pleural invasion is an invasive and aggressive indicator of non-small cell lung cancer. J Thorac Cardiovasc Surg 130:160-165, 2005.
 
513 - Shimizu K (2004)
Shimizu K, Yoshida J, Nagai K, Nishimura M, Yokose T, Ishii G, et al. Visceral pleural invasion classification in non-small cell lung cancer: a proposal on the basis of outcome assessment. J Thorac Cardiovasc Surg 127:1574-1578, 2004.
 
514 - Sibley GS (1998)
Sibley GS, Jamieson TA, Marks LB, Anscher MS, Prosnitz LR. Radiotherapy alone for medically inoperable stage I non-small-cell lung cancer: the Duke experience. Int J Radiat Oncol Biol Phys 40:149-154, 1998.
 
515 - Sienel W (2008)
Sienel W, Dango S, Kirschbaum A, et al. Sublobar resections in stage IA non-small cell lung cancer: Segmentectomies result in significantly better cancer-related survival than wedge resections. Eur J Cardiothorac Surg 33:728–734, 2008.
 
516 - Sikorskii A (2007)
Sikorskii A, Given CW, Given B, Jeon S, Decker V, Becker B, Champion V, McCorkle R. Symptom management for cancer patiënts: A trial comparing two multimodal interventions. J of Pain and Symptom Management 2007, vol 34, no3, 253-264..
 
517 - Silvestri GA (2007)
Silvestri GA, Gould MK, Margolis ML, Tanoue LT, McCrory D, Toloza E, et al. Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest 132:178S-201S, 2007.
 
518 - Silvestri GA (1995)
Silvestri GA, Littenberg B, Colice GL. The clinical evaluation for detecting metastatic lung cancer: a meta-analysis. Am J Respir Care Med 152:225-230, 1995.
 
519 - Silvestri GA (2007)
Silvestri GA, Gould MK, Margolis ML, Tanoue LT, McCrory D, Toloza E, et al. Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest 132:178S-201S, 2007.
 
520 - Sioris T (2000)
Sioris T, Helin H, Jarvenpaa R, Lahdensuo A, Tarkka M. Immuno-staining for detecting lymph node metastases in non-small cell lung cancer. Scand Cardiovasc J 34:536-540, 2000.
 
521 - Sioris T (1999)
Sioris T, Salo J, Perhoniemi V, Mattila S. Surgery for lung cancer in the elderly. Scand Cardiovasc J 33:222-227, 1999
 
522 - Slater JD (1991)
Slater JD, Ellerbroek NA, Barkley HT Jr, Mountain C, Oswald MJ, Roth JA, et al. Radiation therapy following resection of non-small cell bronchogenic carcinoma. Int J Radiat Oncol Biol Phys 20:945-951, 1991.
 
523 - Smith IE (2001)
Smith IE, O’Brian ME, Talbot DC, Nicolson MC, Mansi JL, Hickish TF, et al. Duration of chemotherapy in advanced non-small cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 19:1336-1341, 2001.
 
524 - Smith TJ (2003)
Smith TJ. Evidence-based follow-up of lung cancer patiënts. Semin Oncol 30:361-368, 2003.
 
525 - Smith TP (1984)
Smith TP. Exercise capacity as a predictor of post-thoracotomy morbidity. Am Rev Respir Dis 129:730-734, 1984
 
526 - Smulders SA (2005)
Smulders SA, Smeenk FW, Janssen-Heijnen ML, Wielders PL, de Munck DR, Postmus PE. Surgical mediastinal staging in daily practice. Lung Cancer ;47:243-251, 2005.
 
527 - Snijder RJ (1998)
Snijder RJ, Brutel de la Riviere A, Elbers HJJ, Bosch JMM van den. Survival in resected stage I lung cancer with residual tumor at the bronchial resection margin. Ann Thorac Surg 65:212-216, 1998.
 
528 - Sobin LH (2002)
Sobin LH, Wittekind CH (eds). International Union Against Cancer.TNM classification of malignant tumours. 6th edition. New York: Wiley-Liss, 2002.
 
529 - Socinski MA (2009)
Socinski MA, Langer CJ, Huang JE, et al. Safety of bevacizumab in patiënts with non-small-cell lung cancer and brain metastases. J Clin Oncol 2009;27:5255-5261.
 
530 - Socinski MA (2002)
Socinski MA, Schell MJ, Peterman A, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second line therapy in advanced-stage IIIB/IV non–small-cell lung cancer. J Clin Oncol 20:1335-1343, 2002.
 
531 - Solis LM (2010)
Solis LM, Raso MG, Kalhor N, Behrens C, Wistuba II, Moran CA. Primary oncocytic adenocarcinomas of the lung: a clinicopathologic, immunohistochemical, and molecular biologic analysis of 16 cases. Am J Clin Pathol 133:133-140, 2010.
 
532 - Soon YY (2009)
Soon YY, Stockler MR, Askie LM, Boyer MJ. Duration of chemotherapy for advanced non–small-cell lung cancer: A systematic review and meta-analysis of randomized trials. J Clin Oncol 2009;27; 3277-3283.
 
533 - Soorae AS (1979)
Soorae AS, Stevenson HM. Survival with residual tumor on the bronchial margin after resection for bronchogenic carcinoma. J Thorac Cardiovasc Surg 78:175-180, 1979.
 
534 - Soresi E (1988)
Soresi E, Clerici M, Grilli R, Borghini U, Zucali R, Leoni M, et al. A randomized clinical trial comparing radiation therapy v radiation therapy plus cis-dichlorodiammine platinum (II) in the treatment of locally advanced non-small cell lung cancer. Semin Oncol 15(Suppl 7):20-25, 1988
 
535 - Spiro SG (2004)
Spiro SG, Rudd RM, Souhami RL, Brown RL, Fairlamb DJ, Gower NH, Maslove L, Milroy R, Napp V, Parmar MKB, Peake MD, Stephens RJ, Thorpe H, Waller DA, West P, on behalf of all the Big Lung Trial participants. Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax 59:828-836, 2004.
 
536 - Strauss GM (2008)
Strauss GM, Herndon JE, II, Maddaus MA, Johnstone DW, et al. Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non–Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 26:5043-5051, 2008.
 
537 - Sugi K (1998)
Sugi K, Nawata K, Fujita N, Ueda K, Tanaka T, Matsuoka T, et al. Systematic lymph node dissection for clinically diagnosed peripheral non-small-cell lung cancer less than 2 cm in diameter. World J Surg ;22:290-294, 1998.
 
538 - Sun LM (2000)
Sun LM, Leung SW, Wang CJ, Chen HC, Fang FM, Huang EY, et al. Concomitant boost radiation therapy for inoperable non-small-cell lung cancer: preliminary report of a prospective randomized study. Int J Radiat Oncol Biol Phys 47:41341-8. 2000.
 
539 - Sunaga N (2007)
Sunaga N, Tomizawa Y, Yanagitani N, et al. Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy. Lung Cancer 56:383-389, 2007.
 
540 - Sutani A (2006)

Sutani A, Nagai Y, Udagawa K, et al. Gefitinib for non-small-cell lung cancer patiënts with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. Br J Cancer 95:1483-1489, 2006.

 
541 - Swensen SJ (2009)
Swensen SJ, Silverstein MD, Ilstrup DM, Schleck CD, Edell ES. The probability of malignancy in solitary pulmonary nodules. Application to small radiologically indeterminate nodules. Arch Intern Med. 1997 Apr 28;157(8):849-55.
 
542 - Takamochi K (2005)
Takamochi K, Yoshida J, Murakami K, Niho S, Ishii G, Nishimura M, et al. Pitfalls in lymph node staging with positron emission tomography in non-small cell lung cancer patiënts. Lung Cancer 47:235-242, 2005.
 
543 - Takeda K (2010)
Takeda K, Hida T, Sato T, et al. Randomzed phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patiënts with advanced non-small-cell lung cancer: Results of a West Japan Thoracic Oncology Group Trial (WJTOG0203). J Clin Oncol 28:753-760;2010.
 
544 - Takizawa T (1997)
Takizawa T, Terashima M, Koike T, Akamatsu H, Kurita Y, Yokoyama A. Mediastinal lymph node metastasis in patiënts with clinical stage I peripheral non-small cell lung cancer. J Thorac Cardiovasc Surg 113:248-252, 1997.
 
545 - Talebian M (2009)
Talebian M, von Bartheld MB, Braun J, Versteegh MI, Dekkers OM, Rabe KF, et al. EUS-FNA in the preoperative staging of non-small cell lung cancer. Lung Cancer 2009 Sep 14.
 
546 - Tamura K (2008)
Tamura K, Okamoto I, Kashii T, et al. Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). Br. J. Cancer 98:907-914, 2008.
 
547 - Tatematsu A (2008)
Tatematsu A, Shimizu J, Murakami Y, et al. Epidermal growth factor receptor mutations in small cell lung cancer. Clin Cancer Res 14:6092-6096, 2008.
 
548 - Tedder M (1992)
Tedder M, Anstadt MP, Tedder SD, Lowe JE. Current morbidity, mortality and survival after bronchoplastic procedures for malignancy.Ann Thorac Surg 54:387-391, 1992.
 
549 - Temeck BK (1992)
Temeck BK, Schafer PW, Saini N. Wedge resection for bronchogenic carcinoma in high-risk patiënts. South Med J 85:1-10, 1992.
 
550 - Terzi A (2002)
Terzi A, Lonardoni A, Falezza G, et al. ‘sleeve’-lobectomy for non-small cell lung cancer and carcinoids: results in 160 cases.Eur J Cardiothorac Surg 21:888-893, 2002.
 
551 - Teshima T (1996)
Teshima T, Inoue T, Inoue T, Ikeda H, Marayama S, Yamazaki H, et al. Symptomatic relief for patiënts with osseous metastases treated with radiation and methylprednisolone: a prospective randomised study. Radiat Med 17:411-416, 1996.
 
552 - Thatcher N (2005)
Thatcher N, Chang A,Parikh P, et al. Gefitinib plus best supportive care in previously treated patiënts with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366: 1527–1537, 2005.
 
553 - The Canadian Lung Oncology Group (2001)
The Canadian Lung Oncology Group. Investigating extrathoracic metastatic disease in patiënts with apparently operable lung cancer. Ann Thorac Surg 71:425-434, 2001.
 
554 - The Canadian Lung Oncology Group (1995)
The Canadian Lung Oncology Group. Investigation for mediastinal disease in patiënts with apparently operable lung cancer. Ann Thorac Surg 60:1382-1389 ,1995.
 
555 - Arriagada R (2004)
Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J; International Adjuvant Lung Cancer Trial Collaborative Group.The international adjuvant lung cancer trial collaborative group. Cisplatin-based adjuvant chemotherapy improves survival among patiënts with completely resected non-small-cell lung cancer. New Eng J Med 350,351-360, 2004.
 
556 - The Non-Small Cell Lung Cancer Collaborative Group (1995)
The Non-Small Cell Lung Cancer Collaborative Group. The Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patiënts from 52 randomized clinical trials. BMJ 311:899-909, 1995.
 
557 - Thomas M (2008)
Thomas M, Rube C, Hoffknecht P, Macha HN, Freitag L, Linder A, et al. Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. Lancet Oncol 9:636-648, 2008.
 
558 - Thompson E (2005)
Thompson E, Sola I, Subirana M. Non-invasive interventions for improving well-being and quality of life in patiënts with lung cancer: A systematic review of the evidence. Lung Cancer 2005, vol 50, 163-176.
 
559 - Thun MJ (1997)
Thun MJ, Lally CA, Flannery JT, Calle EE, Flanders WD, Heath CW Jr. Cigarette smoking and changes in histopathology of lung cancer. J Natl Cancer Inst 89:1580-1586, 1997.
 
560 - Thunnissen E (2011)
Thunnissen E, Boers E, Heideman AM, et al. Distinction between pulmonary adenocarcinoma and squamous carcinoma on biopsies. A molecular pathologic analysis. Submitted for publication, 2011.
 
561 - Timmerman R (2006)
Timmerman R, Galvin J, Michalski J, Straube W, Ibbott G, Martin E, Abdulrahman R, Swann S, Fowler J, Choy H. Accreditation and quality assurance for Radiation Therapy Oncology Group: Multicenter clinical trials using Stereotactic Body Radiation Therapy in lung cancer. Acta Oncol 45:779-786, 2006.
 
562 - Timmerman R (2010)
Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, Fakiris A, Bezjak A, Videtic G, Johnstone D, Fowler J, Gore E, Choy H. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 303:1070-1076, 2010.
 
563 - Timmerman (2010)
Timmerman, RD. Surgery Versus Stereotactic Body Radiation Therapy for Early-Stage Lung Cancer: Who's Down for the Count? J Clin Oncol 28: 907-909, 2010.
 
564 - Toloza EM (2003)
Toloza EM, Harpole L, Detterbeck F, McCrory DC. Invasive staging of non-small cell lung cancer: A review of the current evidence. Chest 123:S157-S166, 2003.
 
565 - Toloza EM (2003)
Toloza EM, Harpole L, McCrory DC. Noninvasive staging of non-small cell lung cancer. Chest 123:S137-146. 2003.
 
566 - Tournoy KG (2008)
Tournoy KG, De RF, Vanwalleghem LR, Vermassen F, Praet M, Aerts JG, et al. Endoscopic ultrasound reduces surgical mediastinal staging in lung cancer: a randomized trial. Am J Respir Crit Care Med ;177:531-535, 2008.
 
567 - Tournoy KG (2010)
Tournoy KG, Dooms CA, Rintoul RC, et al. A randomized trial comparing endosonography followed by surgical staging versus surgical mediastinal staging alone in non-small cell lung cancer: The ASTER study. J Clin Oncol 28, suppl 15, 2010 Abstract ASCO Annual Meeting Proceedings (Post-Meeting Edition) abstract 7000.
 
568 - Travis WD (2004)
Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. WHO classification of tumours: Pathology and genetics of tumors of the lung, pleura, thymus and the heart. Lyon, IARC Press, 2004.
 
569 - Travis WD (2008)
Travis WD, Brambilla E, Rami-Porta R, Vallieres E, Tsuboi M, Rusch V, et al. Visceral pleural invasion: pathologic criteria and use of elastic stains: proposal for the 7th edition of the TNM classification for lung cancer. J Thorac Oncol 3:1384-1390, 2008.
 
570 - Travis WD (1999)
Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E. Histological typing of lung and pleural tumors. 3rd edition. New York: Springer Verlag, 1999.
 
571 - Travis (2008)
Travis, William D.; Brambilla, Elisabeth; Rami-Porta, Ramon; Vallières, Eric; Tsuboi, Masahiro; Rusch, Valerie; Goldstraw, Peter; on behalf of the International Staging Committee. Visceral Pleural Invasion: Pathologic Criteria and Use of Elastic Stains: Proposal for the 7th Edition of the TNM Classification for Lung Cancer. J Thor Oncol 3(12):1384-1390, 2008.
 
572 - Thatcher N (2005)
Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patiënts with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366:1527-1537, 2005.
 
573 - Treekoverleg TR-039 (2000)
Treekoverleg TR-039. Notitie ‘Streefnormstelling wachttijden curatieve zorg’. Zeist: Zorgverzekeraars Nederland, 2000.
 
574 - Treekoverleg TR-039 (2000)
Treekoverleg TR-039. Notitie ‘Streefnormstelling wachttijden curatieve zorg’. Zeist: Zorgverzekeraars Nederland, 2000.
 
575 - Tronc F (1999)
Tronc F, Gregoire J, Rouleau J, Deslauriers J. Techniques of pneumonectomy. Completion pneumonectomy. Chest Surg Clin N Am 9:393-405, 1999.
 
576 - Tronc P (2000)
Tronc P, Gregoire J, Rouleau J, Deslauriers J. Long term results of ‘sleeve’-lobectomy for lung cancer. Eur J Cardiothorc Surg 17:550-556, 2000.
 
577 - Trovo MG (1992)
Trovo MG, Minatel E, Franchin G, Boccieri MG, Nascimben O, Bolzicco G, et al. Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys 24:11-5, 1992.
 
578 - Tsao MS (2005)
Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer: Molecular and clinical predictors of outcome. N Engl J Med 353:133–144, 2005.
 
579 - Tsubota N (1998)
Tsubota N, Ayabe K, Doi O, Mori T, Namikawa S, Taki T, et al. Ongoing prospective study of segmentectomy for small lung tumors. Ann Thorac Surg 66:1787-1790, 1998.
 
580 - Tsuchiya R (1994)
Tsuchiya R, Asamura H, Kondo H, Goya T, Naruke T. Extended resection of the left atrium, great vessels, or both for lung cancer. Ann Thorac Surg 57:960-965, 1994.
 
581 - Tsuchiya R (1990)
Tsuchiya R, Goya T, Naruke T, Suemasu K. Resection of tracheal carcinoma for lung cancer. J Thorac Cardiovasc Surg 99:779-87, 1990.
 
582 - Uematsu M (2002)
Uematsu M. CT-guided stereotactic radiotherapy for early stage lung cancer. Nippon Rinsho 60 Suppl 5:408-410, 2002.
 
583 - Uitterhoeve AL (2007)
Uitterhoeve AL, Koolen MG, van Os RM et al. Accelerated high-dose radiotherapy alone or combined with either concomitant or sequential chemotherapy; treatments of choice in patiënts with Non-Small Cell Lung Cancer. Radiot Oncol 2007 2:27-.., 2007.
 
584 - Ulutin HC (2000)
Ulutin HC, Güden M, Oysul K, Sürenkök S, Pak Y. Split-course radiotherapy with or without concomitant or sequential chemotherapy in non-small cell lung cancer. Radiation Medicine ;18:93-96, 2000.
 
585 - Ung YC (2007)
Ung YC, Maziak DE, Vanderveen JA, Smith CA, Gulenchyn K, Lacchetti C, et al. 18Fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer: a systematic review. J Natl Cancer Inst 99:1753-1767, 2007.
 
586 - Ushiki A (2009)
Ushiki A, Koizumi T, Kobayashi N, et al. Genetic heterogeneity of EGFR mutation in pleomorphic carcinoma of the lung: response to gefitinib and clinical outcome. Jpn J Clin Oncol 39:267-270, 2009.
 
587 - Groen HJ (2003)
Groen HJ, Meerbeeck JP van. Richtlijn maligne pleurale effusies. Nederlandse Vereniging van Artsen voor Longziekten en Tuberculose, 2003
 
588 - Van den WT (2006)
Van den WT, Huizing MT, Vermorken JB. Bisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy? Ann Oncol 17:1197-1204, 2006.
 
589 - Van der Linden YM (2004)
Van der Linden YM, Dijkstra PDS, Kroon HM, Lok JJ, PhD, Noordijk EM, Leer JWH, Marijnen CAM. Comparative analysis of risk factors for pathological fracture with femoral metastases. J Bone and Joint Surg86-B:566-573, 2004.
 
590 - van Geel AN (2003)
van Geel AN, Jansen PP, van Klaveren RJ, et al. High relapse-free survival after preoperative and intraoperative radiotherapy and resection for sulcus superior-tumors. Chest 124:1841-1846, 2003.
 
591 - Van Meerbeeck JP (2007)
Van Meerbeeck JP, Kramer GW, Van Schil PE, Legrand C, Smit EF, Schramel F, et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst 99:442-450; 2007.
 
592 - Van SP (2005)
Van SP, van MJ, Kramer G, Splinter T, Legrand C, Giaccone G, et al. Morbidity and mortality in the surgery arm of EORTC 08941 trial. Eur Respir J 26:192-197; 2005.
 
593 - van Tinteren H (2002)
van Tinteren H, Hoekstra OS, Smit EF, et al. Effectiveness of positron emission tomography in the preoperative assessment of patiënts with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. The Lancet 359:1388-1392, 2002.
 
594 - Varela G (2001)
Varela G, Cordovilla R, Jimenez MF, Novoa N. Utility of standardized exercise oximetry to predict cardiopulmonary morbidity after lung resection. Eur J Cardio Thorac Surg 2001;19:351-4 .
 
595 - Verhagen AF (2004)
Verhagen AF, Bootsma GP, Tjan-Heijnen VC, van der Wilt GJ, Cox AL, Brouwer MH, et al. FDG-PET in staging lung cancer: how does it change the algorithm? Lung Cancer 44:175-181, 2004.
 
596 - Viney RC (2004)
Viney RC, Boyer MJ, King MT, Kenny PM, Pollicino CA, McLean JM, McCaughan BC, Fulham MJ. Randomized controlled trial of the role of positron emission tomography in the management of stage I and II non-small-cell lung cancer. J Clin Oncol 22:2357-2362, 2004.
 
597 - Vijayakumar S (1991)
Vijayakumar S, Myrianthopoulos LC, Rosenberg I, Halpern HJ, Low N, Chen GT. Optimization of radical radiotherapy with beam’s eye view techniques for non-small cell lung cancer. Int J Radiat Oncol Biol Phys 21:779-788, 1991.
 
598 - Vogt-Moykopf I (1973)
Vogt-Moykopf I, Fritz T, Meyer G, Bulzerbruck H, Daskos G. Bronchoplastic and angioplastic operation in bronchial carcinoma: long term results of a retrospective analysis from 1973 to 1983. Intern Surg 71:211-220,1986.
 
599 - Voltolini L (2000)
Voltolini L, Paladini P, Luzzi L, Ghiribelli C, Bisceglie M di, Gotti G. Iterative surgical resections for local recurrent and second primary bronchogenic carcinoma. Eur J Cardiothorac Surg 18:529-534, 2000.
 
600 - von Plessen C (2006)
von Plessen C, Bergman B, Andresen O, et al: Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer. Br J Cancer 95:966-973, 2006.
 
601 - Vos PJ (2001)
Vos PJ, Remie ME. Psychotherapeutische groepsbegeleiding voor vrouwen met borstkanker. In: Haes JCJM de, Gualtherie van Weezel LM, Sanderman R, Wiel HBM van der (red). Psychologische patientenzorg in de oncologie; handboek voor de professional. Assen: Van Gorcum, 175-179, 2001.
 
602 - Wagner J jr (1994)
Wagner J jr, Lad T, Piantadosi S, Ruckdeschel JC. Randomized phase 2 evaluation of preoperative radiation therapy and preoperative chemotherapy with mitomycin, vinblastine, and cisplatin in patiënts with technically unresectable stage IIIA and IIIB non-small cell cancer of the lung LCSG 881. Chest 106(Suppl 6):S348-354, 1994.
 
603 - Wallace MB (2008)
Wallace MB, Pascual JM, Raimondo M, Woodward TA, McComb BL, Crook JE, et al. Minimally invasive endoscopic staging of suspected lung cancer. JAMA ;299:540-546, 2008.
 
604 - Waller D (2004)
Waller D, Peake MD, Stephens RJ, Gower NH, Milroy R, Parmar MKB, Rudd RM, Spiro SG. Chemotherapy for patiënts with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothor Surg 26,173-182,2004.
 
605 - Walsh GL (1995)
Walsh GL, O’Connor M, Willis KM, Milas M, Wong RS, Nesbitt JC, et al. Is follow-up of lung cancer patiënts after resection medically indicated and cost-effective? Ann Thor Surg 60:1563-570, 1995.
 
606 - Walsh GL (1994)
Walsh GL. Resection of lung cancer is justified in high-risk patiënts selected by exercise oxygen consumption. Ann Thorac Surg 58:704-710; discussion 711, 1994.
 
607 - Walter J. Scott WJ (2010)
Walter J. Scott WJ, Allen MS, Darling G, et al. Video-assisted thoracic surgery versus open lobectomy for lung cancer: A secondary analysis of data from the American College of Surgeons Oncology Group Z0030 randomized clinical trial J Thorac Cardiovasc Surg ;139:976-983, 2010.
 
608 - Wang J (1999)
Wang J. Diffusing capacity predicts operative mortality but not long-term survival after resection for lung cancer. J Thorac Cardiovasc Surg 117:581-586; discussion 586-7, 1999
 
609 - Wang J (1999)
Wang J. Diffusing capacity predicts operative mortality but not long-term survival after resection for lung cancer. J Thorac Cardiovasc Surg 117:581-6; discussion 586-587, 1999.
 
610 - Wang XT (2005)
Wang XT, Sienel W, Eggeling S, Ludwig C, Stoelben E, Mueller J, Klein CA, Passlick B. Detection of disseminated tumor cells in mediastinoscopic lymph node biopsies and lymphadenectomy specimens of patiënts with NSCLC by quantitative RT-PCR. Eur J Cardiothorac Surg 28:26-32, 2005.
 
611 - Warram J (1975)
Warram J. Preoperative irradiation of cancer of the lung: final report of a therapeutic trial. A collaborative study. Cancer 36:914-925, 1975.
 
612 - Warren WH (1994)
Warren WH, Faber LP. Segmentectomy vs lobectomy in patiënts with stage I pulmonary carcinoma. J Thorac Cardiovasc Surg 107:1087-1094, 1994.
 
613 - Watanabe Y (1990)
Watanabe Y, Shimizu J, Oda M. Results in 104 patiënts undergoing bronchoplastic procedures for bronchial lesions. Ann Thorac Surg 50:607-614, 1990
 
614 - Watanabe Y (1990)
Watanabe Y, Shimizu J, Tsubota M, Iwa T. Mediastinal spread of metastatic lymph nodes in bronchogenic carcinoma. Mediastinal nodal metastasis in lung cancer. Chest 1990;1059-1065, 1990.
 
615 - Webb WR (1991)
Webb WR, Gatsonis C, Zerhouni EA, Heelan RT, Glazer GM, Francis IR, et al. CT and MR imaging in staging nonsmall cell bronchogenic carcinoma: report of the Radiologic Diagnostic Oncology Group. Radiology 178:705-713, 1991.
 
616 - Weisman AD (1976)
Weisman AD, Worden JW. The existential plight in cancer: significance of the first 100 days. Int J Psychiatry Med 77;7(1):1-15, 1976.
 
617 - Weiss GJ (2006)
Weiss GJ, Langer C, Rosell R, et al. Elderly patiënts benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patiënts with previously treated advanced non-small-cell lung cancer. J Clin Oncol 24:4405-4411, 2006.
 
618 - Weiss GJ (2006)
Weiss GJ, Langer C, Rosell R, et al. Elderly patiënts benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patiënts with previously treated advanced non-small-cell lung cancer. J Clin Oncol 24:4405-4411, 2006.
 
619 - Weissberg D (1993)
Weissberg D, Straehley CJ, Scully NM, Margulies D. Less than lobar resections for bronchogenic carcinoma. Scand Thorac Cardiovasc Surg 27:121-6, 1993.
 
620 - Weksler B (1997)
Weksler B, Bains M, Burt M, Downey R, Martini N, Rusch V, Ginsberg R. Resection of lung cancer invading the diaphragm. J Thorac Cardiovasc Surg 114:500-501, 1997.
 
621 - West HL (2006)
West HL, Franklin WA, McCoy J, Gumerlock PH, Vance R, Lau DH, Chansky K, Crowley JJ, Gandara DR. Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126. J Clin Oncol 24:1807-1813, 2006.
 
622 - Westeel V (2000)
Westeel V, Choma D, Clement F, Woronoff-Lemsi MC, Pugin JF, Dubiez A, et al. Relevance of an intensive postoperative follow-up after surgery for non-small cell lung cancer. Ann Thorac Surg 70:1185-1190, 2000.
 
623 - Whitehouse JMA (1994)
Whitehouse JMA. Management of lung cancer – current clinical practices: report of a working group. London: Standing Medical Advisory Committee, 1994.
 
624 - Wiel HBM van der (2001)
Wiel HBM van der, Kooij A, Garssen B, Gualtherie van Weezel LM. Verwerken, is erbij te helpen? In: Haes JCJM de, Gualtherie van Weezel LM, Sanderman R, Wiel HBM van der (red). Psychologische patiëntenzorg in de oncologie; handboek voor de professional. Assen: Van Gorcum, 92-102, 2001.
 
625 - Winton T (2005)
Winton T, Rigas J, Cormier Y, et al. for the National Cancer Institute of Canada Clinical Trials Group and the National Cancer Institute of the United States Intergroup JBR.10 Trial Investigators. Vinorelbine plus cisplatin versus observation in resected Non–Small-Cell Lung Cancer. New Eng J Med 352,2589-2597, 2005.
 
626 - Wislez M (2010)
Wislez M, Antoine M, Baudrin L, et al. Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib. Lung Cancer 68:185-191, 2010.
 
627 - Witte B (2008)
Witte B, Neumeister W, Huertgen M. Does endoesophageal ultrasound-guided fine-needle aspiration replace mediastinoscopy in mediastinal staging of thoracic malignancies? Eur J Cardiothorac Surg ;33:1124-1128, 2008.
 
628 - World Health Organization WHO (1996)
World Health Organization WHO. Cancer Pain Relief: With a Guide to Opioid Availability, (2nd edn) Geneva, Switzerland: World Health Organization, 1996.
 
629 - Wouters MW (2010)
Wouters MW, Siesling S, Jansen-Landheer ML, Elferink MA, Belderbos J, Coebergh JW, Schramel FM. Variation in treatment and outcome in patients with non-small cell lung cancer by region, hospital type and volume in the Netherlands. Eur. J. Surg. Oncol Suppl1: s83-92, 2010.
 
630 - Wu MT (2002)
Wu MT, Pan HB, Chiang AA, Hsu HK, Chang HC, Peng NJ, et al. Prediction of postoperative lung function in patiënts with lung cancer: comparison of quantitative CT with perfusion scintigraphy. Am J Roentgenol 178:667-672, 2002.
 
631 - Wu Y (2002)
Wu Y, Huang ZF, Wang SY, Yang XN, Ou W. A randomized trial of systematic nodal dissection in resectable non-small cell lung cancer. Lung Cancer ;36:1-6, 2002.
 
632 - Wu YL (2007)
Wu YL, Zhong WZ, Li LY, et al: Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patiënts with non-small cell lung cancer: A meta-analysis based on updated individual patiënt data from six medical centers in mainland China. J Thorac Oncol 2:430-439, 2007.
 
633 - Yan TD (2009)
Yan TD, Black D, Bannon PG, McCaughan BC. Systematic Review and Meta-Analysis of Randomized and Nonrandomized Trials on Safety and Efficacy of Video-Assisted Thoracic Surgery Lobectomy for Early-Stage Non–Small-Cell Lung Cancer. J Clin Oncol, 2553-2562, 2009.
 
634 - Yang W (2008)
Yang W, Fu Z, Yu J, Yuan S, Zhang B, Li D, et al. Value of PET/CT versus enhanced CT for locoregional lymph nodes in non-small cell lung cancer. Lung Cancer 61:35-43, 2008.
 
635 - Yasufuku K (2006)
Yasufuku K, Nakajima T, Motoori K, Sekine Y, Shibuya K, Hiroshima K, et al. Comparison of endobronchial ultrasound, positron emission tomography, and CT for lymph node staging of lung cancer. Chest ;130:710-718, 2006.
 
636 - Yasumoto K (2003)
Yasumoto K, Osaki T, Watanabe Y, Kato H, Yoshimura T. Prognostic value of cytokeratin-positive cells in the bone marrow and lymph nodes of patiënts with resected nonsmall cell lung cancer: a multicenter prospective study. Ann Thorac Surg 76:194-201, 2003; discussion 202.
 
637 - Yatsuyanagi E (2000)
Yatsuyanagi E, Hirata S, Yamazaki K, Sasajima T, Kubo Y. Anastomotic complications after bronchoplastic procedures for nonsmall cell lung cancer. Ann Thorac Surg 70:396-400, 2000.
 
638 - Yoshikawa K (2002)
Yoshikawa K, Tsubota N, Kodama K, Ayabe H, Taki T and Mori T. Prospective study of extended segmentectomy for small lung tumors: the final report. Ann Thorac Surg 73:1055-1059, 2002.
 
639 - Younes RN (1999)
Younes RN, Gross JL, Deheinzelin D. Follow-up in lung cancer: how often and for what purpose? Chest 115:1494-499, 1999.
 
640 - Yun M (2001)
Yun M, Kim W, Alnafisi N, Lacorte L, Jang S, Alavi A. 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI. J Nucl Med 42:1795-1799, 2001.
 
641 - Zabora J (2001)
Zabora J, BrintzenhofeSzoc K, Curbow B, Hooker C, Piantadosi S. The prevalence of psychological distress by cancer site. Psycho-oncology 10:19-28, 2001.
 
642 - Zakowski MF (2006)
Zakowski MF, Ladanyi M, Kris MG. EGFR mutations in small-cell lung cancers in patiënts who have never smoked [letter]. N Engl J Med 355:213-215, 2006.
 
643 - Zatloukal P (2004)
Zatloukal P, Petruzelka L, Zemanova M, et al. Concomitant versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 46: 87-98, 2004.
 
644 - Zeiher BG (1995)
Zeiher BG, Gross TJ, Kern JA, Lanza LA, Peterson MW. Predicting postoperative pulmonary function in patiënts undergoing lung resection. Chest 108:68-72, 1995.
 
645 - Zhu CQ (2008)
Zhu CQ, da Cunha Santos G, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR. 21. J Clin Oncol 26:4268–4275, 2008.
 
646 - Zieren HU (1994)
Zieren HU, Muller JM, Petermann D, Pichlmaier H. [The effectiveness of standardized follow-up studies after resection of non-small cell bronchial carcinoma]. Langenbecks Arch Chir 379:299-306, 1994.
 
647 - Gibbs A.R. (2000)

Gibbs AR, Attanoos RL. Examination of lung specimens. J Clin Path 53:507-512, 2000.

 
647 - Antoch G (2003)
Antoch G, Stattaus J, Nemat AT, Simone Marnitz S, et al. Non-Small Cell Lung Cancer: Dual-Modality PET/CT in Preoperative Staging. Radiology 229:526-533, 2003.
 
648 - Szlubowski et al. (2009)
Szlubowski et al. A combined approach of endobronchial and endoscopic ultrasound guided needle aspiration in the radiologically normal mediastinumin NSCLC staging - a prospective trail. Eur J Cardiothoracic Surg 2009, dec 18, epub.
 
649 - Herth FJ (2006)

Herth FJ, Ernst A, Eberhardt R, Vilmann P, Dienemann H, Krasnik M. Endobronchial ultrasound-guided transbronchial needle aspiration of lymph nodes in the radiologically normal mediastinum. Eur Respir J ;28:910-914, 2006.

 
650 - Bozcuk H (2006)

Bozcuk H, Dalmis B, Samur M, Ozdoagan M, Artac M, Savas B. Quality of life in patiënts with advanced non-small cell lung cancer. Cancer Nursing, 2006, vol 29, no2 104-110.

 
651 - Kwaliteitskader organisatie oncologische zorg (2009)

Kwaliteitskader organisatie oncologische zorg. Utrecht:

 
652 - Elderly Lung Cancer Vinorelbine Italian Study (1999)

Elderly Lung Cancer Vinorelbine Italian Study (ELVIS) Group. Effects of vinorelbine on quality of life and survival of elderly patiënts with advanced non-small-cell lung cancer. J Natl Cancer Inst 91:66-72, 1999.

 
653 - PORT Meta-analysis Trialists Group (1998)
 PORT Meta-analysis Trialists Group. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patiënt data from nine randomised controlled trials. Lancet 352:257-63, 1998.
 
654 - Andolino DL (2011)
Andolino DL, Forquer JA, Henderson MA, Barriger RB, Shapiro RH, Brabham JG, et al. Chest wall toxicity after stereotactic body radiotherapy for malignant lesions of the lung and liver. Int J Radiat Oncol Biol Phys 2011;80(3):692-697.
 
655 - Ashworth A (2013)
Ashworth A, Rodrigues G, Boldt G, et al. Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature. Lung Cancer 2013;82(2):197-203.
 
656 - Atagi S (2012)
Atagi S, Kawahara M, Yokoyama A, et al. Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301). Lancet Oncol 2012;13(7):671-8.
 
657 - Baardwijk van A (2012)
Baardwijk van A, Tome W, Elmpt van W, et al. Is high-dose stereotactic body radiotherapy (SBRT) for stage I non-small cell lung cancer (NSCLC) overkill? A systematic review. Radiother Oncol 2012;105(2):145-149.
 
658 - Ball D (2013)
Ball D, Fisher RJ, Burmeister B, et al. The complex relationship between lung tumor volume and survival in patients with non-small cell lung cancer treated by definitive radiotherapy: a prospective, observational prognostic factor study of the Trans-Tasman Radiation Oncology Group (TROG 99.05). Radiother Oncol 2013;106(3):305-11.
 
659 - Ball D (2013)
Ball D, Mitchell A, Giroux D, et al. Effect of tumor size on prognosis in patients treated with radical radiotherapy or chemoradiotherapy for non-small cell lung cancer. An analysis of the staging project database of the International Association for the Study of Lung Cancer. J Thorac Oncol. 2013;8(3):315-21.
 
660 - Billiet C
Billiet C, Decaluwé H, Peeters S, et al. Modern post-operative radiotherapy for stage III non-small cell lung cancer may improve local control and survival: A meta-analysis. Radiother Oncol. 2014 Jan;110(1):3-8. 
 
661 - Bradley J (2013)
Bradley J, Masters G, Hu C, et al. PL03.05 An intergroup randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) chemoradiotherapy (CRT) +/- cetuximab (cetux) for stage III non-small cell lung cancer (NSCLC): Results on cetux from RTOG 0617. J Thor Oncol 2013;8 (11, Supplement 2): S3.
 
662 - Chang J (2008)
Chang J, Balter P, Dong L, et al. Stereotactic Body Radiation Therapy in Centrally and Superiorly Located Stage I or Isolated Recurrent Non-Small-Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):967-71.
 
663 - Chen C (2013)
Chen C, Uyterlinde W, Sonke J, et al. Severe late esophagus toxicity in NSCLC patients treated with IMRT and concurrent chemotherapy. Radiother Oncol 2013;108(2):337-41.
 
664 - Curran WJ Jr (2011)
Curran WJ Jr, Paulus R, Langer CJ, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst 2011;103(19):1452-60.
 
665 - De Ruysscher D (2012)
De Ruysscher D, Wanders R, Baardwijk van A, et al. Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450). J Thorac Oncol. 2012;7(10):1547-55.
 
666 - Dehing-Oberije C (2008)
Dehing-Oberije C, De Ruysscher D, van der Weide H, et al. Tumor volume combined with number of positive lymph node stations is a more important prognostic factor than TNM stage for survival of non-small-cell lung cancer patients treated with (chemo)radiotherapy. Int J Radiat Oncol Biol Phys 2008;70(4):1039-44.
 
667 - Fernando HC (2012)
Fernando HC, Timmerman R. American College of Surgeons Oncology Group Z4099/Radiation Therapy Oncology Group 1021: a randomized study of sublobar resection compared with stereotactic body radiotherapy for high-risk stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 2012;144(3):S35-8.
 
668 - Govaert SL (2012)
Govaert SL, Troost EG, Schuurbiers OC, et al. Treatment outcome and toxicity of intensity-modulated (chemo) radiotherapy in stage III non-small cell lung cancer patients. Radiat Oncol. 2012;7:150.
 
669 - Govindan R (2011)
Govindan R, Bogart J, Stinchcombe T, et al. Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407. J Clin Oncol 2011;29(23):3120-5.
 
670 - Grills IS (2012)
Grills IS, Hope AJ, Guckenberger M, et al. A collaborative analysis of stereotactic lung radiotherapy outcomes for early-stage non-small-cell lung cancer using daily online cone-beam computed tomography image-guided radiotherapy. J Thorac Oncol 2012;7(9):1382-1393.
 
671 - Guckenberger M (2010)
Guckenberger M, Baier K, Polat B, Richter A, Krieger T, Wilbert J, et al. Dose-response relationship for radiation-induced pneumonitis after pulmonary stereotactic body radiotherapy. Radiotherapy and Oncology 2010 10;97(1):65-70.
 
672 - Haasbeek CJ (2011)
Haasbeek CJ, Lagerwaard FJ, Slotman BJ, et al. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. J Thorac Oncol 2011;6(12):2036-2043.
 
673 - Harkenrider M (2013)
Harkenrider M, Bertke M, Dunlap N. Stereotactic Body Radiation Therapy for Unbiopsied Early-stage Lung Cancer: A Multi-Institutional Analysis. Am J Clin Oncol. 2014 Aug;37(4):337-42
 
674 - Hasselle M (2012)
Hasselle M, Haraf D, Rusthoven K, et al. Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. J Thorac Oncol. 2012;7(2):376-81.
 
675 - Heuvel van den M (2013)
Heuvel van den M, Uyterlinde W, Vincent AD, et al. Additional weekly Cetuximab to concurrent chemoradiotherapy in locally advanced non-small cell lung carcinoma: Efficacy and safety outcomes of a randomized, multi-center phase II study investigating. Radiother Oncol. 2014 Jan;110(1):126-31.
 
676 - Huang K (2012)
Huang K, Dahele M, Senan S, et al. Radiographic changes after lung stereotactic ablative radiotherapy (SABR)--can we distinguish recurrence from fibrosis? A systematic review of the literature. Radiother Oncol 2012;102(3):335-42.
 
677 - Huang K (2012)
Huang K, Dahele M, Senan S, et al. Radiographic changes after lung stereotactic ablative radiotherapy (SABR)--can we distinguish recurrence from fibrosis? A systematic review of the literature. Radiother Oncol 2012;102(3):335-342.
 
678 - Hubbard MO (2012)
Hubbard MO, Fu P, Margevicius S, et al. Five-year survival does not equal cure in non-small cell lung cancer: a Surveillance, Epidemiology, and End Results-based analysis of variables affecting 10- to 18-year survival. J Thorac Cardiovasc Surg 2012;143(6):1307-13.
 
679 - Jeppesen S (2013)
Jeppesen S, Schytte T, Jensen H, et al. Stereotactic body radiation therapy versus conventional radiation therapy in patients with early stage non-small cell lung cancer: An updated retrospective study on local failure and survival rates. Acta Oncol 2013;52(7):1552-1558.
 
680 - Karlsson K (2013)
Karlsson K, Nyman J, Baumann P, et al. Retrospective cohort study of bronchial doses and radiation-induced atelectasis after stereotactic body radiation therapy of lung tumors located close to the bronchial tree. Int J Radiat Oncol Biol Phys 2013;87(3):590-595.
 
681 - Kelly K (2008)
Kelly K, Chansky K, Gaspar L, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol. 2008;26(15):2450-6.
 
682 - Koh P (2012)
Koh P, Faivre-Finn C, Blackhall F, et al. Targeted agents in non-small cell lung cancer (NSCLC): Clinical developments and rationale for the combination with thoracic radiotherapy. Cancer Treat Rev 2012;38(6):626-40.
 
683 - Koning CC (2013)
Koning CC, Wouterse SJ, Daams JG, et al. Toxicity of concurrent radiochemotherapy for locally advanced non-small-cell lung cancer: a systematic review of the literature. Clin Lung Cancer 2013;14(5):481-7.
 
684 - Lagerwaard F (2012)
Lagerwaard F, Aaronson N, Gundy C, et al. Patient-reported quality of life after stereotactic ablative radiotherapy for early-stage lung cancer. J Thorac Oncol 2012;7(7):1148-1154.
 
685 - Lagerwaard FJ (2012)
Lagerwaard FJ, Verstegen NE, Haasbeek CJ, et al. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2012;83(1):348-53.
 
686 - Liao Z (2010)
Liao Z, Komaki R, Thames H Jr, Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. Int J Radiat Oncol Biol Phys 2010;76(3):775-81.
 
687 - Lind JS (2012)
Lind JS, Senan S, Smit EF. Pulmonary toxicity after bevacizumab and concurrent thoracic radiotherapy observed in a phase I study for inoperable stage III non-small cell lung cancer. J Clin Oncol 2012; 30(8):e104-8.
 
688 - Liu H (2012)
Liu H, Zhang X, Vinogradskiy Y, Swisher S, et al. Predicting radiation pneumonitis after stereotactic ablative radiation therapy in patients previously treated with conventional thoracic radiation therapy. Int J Radiat Oncol Biol Phys 2012;84(4):1017-1023.
 
689 - Lopez Guerra J (2012)
Lopez Guerra J, Gomez D, Zhuang Y et al. Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosis. Int J Radiat Oncol Biol Phys. 2012;84(1):e61-7.
 
690 - Louie AV (2013)
Louie AV, Senthi S, Palma DA. Surgery versus SABR for NSCLC. Lancet Oncol 2013;14(12):e491.
 
691 - Milano M (2008)
Milano M, Katz A, Schell M, et al. Descriptive analysis of oligometastatic lesions treated with curative-intent stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2008;72(5):1516-22.
 
692 - Milano MT (2012)
Milano MT, Katz AW, Zhang H, Okunieff P. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys 2012;83(3):878-86.
 
693 - Milano MT (2009)
Milano MT, Philip A, Okunieff P. Analysis of patients with oligometastases undergoing two or more curative-intent stereotactic radiotherapy courses. Int J Radiat Oncol Biol Phys. 2009;73(3):832-7.
 
694 - Moghanaki D (2013)
Moghanaki D, Karas T. Surgery versus SABR for NSCLC. Lancet Oncol 2013;14(12):e490-1.
 
695 - Mutter RW (2012)
Mutter RW, Liu F, Abreu A, Yorke E, Jackson A, Rosenzweig KE. Dose-volume parameters predict for the development of chest wall pain after stereotactic body radiation for lung cancer. Int J Radiat Oncol Biol Phys 2012;82(5):1783-1790.
 
696 - Nestle U (2013)
Nestle U, Faivre-Finn C, Deruysscher D, et al. Stereotactic body radiotherapy (SBRT) in central non-small cell lung cancer (NSCLC): Solid evidence or "no-go"? Radiother Oncol. 2013;109(1):178-9.
 
697 - Nuyttens J (2012)
Nuyttens J, van der Voort van Zyp,N, et al. Outcome of four-dimensional stereotactic radiotherapy for centrally located lung tumors. Radiother Oncol 2012;102(3):383-387.
 
698 - Onishi H (2011)
Onishi H, Shirato H, Nagata Y, Hiraoka M, et al. Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery? Int J Radiat Oncol Biol Phys 2011;81(5):1352-8.
 
699 - Palma D (2012)
Palma D, Lagerwaard F, Rodrigues G, Haasbeek C, Senan S. Curative treatment of Stage I non-small-cell lung cancer in patients with severe COPD: stereotactic radiotherapy outcomes and systematic review. Int J Radiat Oncol Biol Phys 2012;82(3):1149-1156.
 
700 - Palma DA (2013)
Palma DA, Senan S, Oberije C, et al. Predicting esophagitis after chemoradiation therapy for non-small cell lung cancer: an individual patient data meta-analysis. Int J Radiat Oncol Biol Phys 2013;87(4):690-6.
 
701 - Palma DA (2013)
Palma DA, Senan S, Tsujino K, et al. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. Int J Radiat Oncol Biol Phys 20131;85(2):444-50.
 
702 - Péchoux C Le (2013)
Péchoux C Le, Mercier O, Belemsagha D, et al. Role of adjuvant radiotherapy in completely resected non-small-cell lung cancer. Eur J Cancer Supplements 2013;11(2):123-130.
 
703 - Pepek J (2011)
Pepek J, Chino J, Marks L, et al. How Well Does the New Lung Cancer Staging System Predict for Local/Regional Recurrence After Surgery? J Thorac Oncol 2011;6:757-761.
 
704 - Peters N (2008)
Peters N, Richel D, Verhoeff J, et al. Bowel Perforation After Radiotherapy in a Patient Receiving Sorafenib. J Clin Oncol 2008;26(14):2405-6.
 
705 - Rowe B (2012)
Rowe B, Boffa D, Wilson L, et al. Stereotactic body radiotherapy for central lung tumors. J Thorac Oncol 2012;7(9):1394-1399.
 
706 - Ruysscher de D (2013)
Ruysscher de D, Sharifi H, Defraene G, et al. Quantification of radiation-induced lung damage with CT scans: the possible benefit for radiogenomics. Acta Oncol 2013;52(7):1405-10.
 
707 - Salama J (2012)
Salama J, Hasselle M, Chmura S, et al. Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer 2012;118(11):2962-70.
 
708 - Salama JK (2013)
Salama JK, Vokes E. New radiotherapy and chemoradiotherapy approaches for non-small-cell lung cancer. J Clin Oncol 2013;31(8):1029-38.
 
709 - Schil van P (2013)
Schil van P, Meerbeeck van J. Surgery or radiotherapy for early-stage lung cancer--a potential comparison bias. Lancet Oncol 2013;14(10):e390.
 
710 - Schwarz M (2005)
Schwarz M, Alber M, Lebesque J, et al. Dose heterogeneity in the target volume and intensity-modulated radiotherapy to escalate the dose in the treatment of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2005;62(2):561-70.
 
711 - Senan S (2013)
Senan S, Paul M, Lagerwaard F. Treatment of early-stage lung cancer detected by screening: surgery or stereotactic ablative radiotherapy? Lancet Oncol 2013;14(7):e270-4.
 
712 - Senthi S (2013)
Senthi S, Dahele M, Slotman B, et al. Investigating strategies to reduce toxicity in stereotactic ablative radiotherapy for central lung tumors. Acta Oncol. 2014 Mar;53(3):330-5
 
713 - Senthi S (2013)
Senthi S, Haasbeek C, Slotman BJ, et al. Outcomes of stereotactic ablative radiotherapy for central lung tumours: a systematic review. Radiother Oncol 2013;106(3):276-282.
 
714 - Senthi S (2012)
Senthi S, Lagerwaard F, Haasbeek C, et al. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis. Lancet Oncol 2012;13(8):802-809.
 
715 - Solda F (2013)
Solda F, Lodge M, Ashley S, et al. Stereotactic radiotherapy (SABR) for the treatment of primary non-small cell lung cancer; Systematic review and comparison with a surgical cohort. Radiother Oncol 2013;109(1):1-7.
 
716 - Soliman M (2013)
Soliman M, Yaromina A, Appold S, et al. GTV differentially impacts locoregional control of non-small cell lung cancer (NSCLC) after different fractionation schedules: subgroup analysis of the prospective randomized CHARTWEL trial. Radiother Oncol 2013;106(3):299-304.
 
717 - Sonke J (2010)
Sonke J, Belderbos J. Adaptive radiotherapy for lung cancer. Semin Radiat Oncol. 2010;20(2):94-106.
 
718 - Stabenau H (2011)
Stabenau H, Rivera L, Yorke E, et al. Reduced order constrained optimization (ROCO): clinical application to lung IMRT. Med Phys 2011;38(5):2731-41.
 
719 - Stephans KL (2012)
Stephans KL, Djemil T, Tendulkar RD, et al. Prediction of chest wall toxicity from lung stereotactic body radiotherapy (SBRT). Int J Radiat Oncol Biol Phys 2012;82(2):974-980.
 
720 - Takeda A (2012)
Takeda A, Kunieda E, Ohashi T, et al. Severe COPD is correlated with mild radiation pneumonitis following stereotactic body radiotherapy. Chest 2012;141(4):858-866.
 
721 - Takeda A (2014)
Takeda A, Sanuki N, Enomoto T, et al. Subclinical interstitial lung disease: Is it a risk factor for fatal radiation pneumonitis following stereotactic body radiotherapy? Lung Cancer 2014;83(1):112.
 
722 - Taremi M (2012)
Taremi M, Hope A, Lindsay P, et al. Predictors of radiotherapy induced bone injury (RIBI) after stereotactic lung radiotherapy. Radiat Oncol 2012 ;7:159-717X-7-159.
 
723 - Timmerman RD (2013)
Timmerman RD, Fernando HC. A radiation oncologist's and thoracic surgeon's view on the role of stereotactic ablative radiotherapy for operable lung cancer. Semin Thorac Cardiovasc Surg 2013;25(1):8-13.
 
724 - Tree A (2013)
Tree A, Khoo V, Eeles R, Ahmed M, et al. Stereotactic body radiotherapy for oligometastases. Lancet Oncol. 2013;14(1):e28-37.
 
725 - Uyterlinde W (2013)
Uyterlinde W, Belderbos J, Baas C, et al. Prediction of acute toxicity grade ? 3 in patients with locally advanced non-small-cell lung cancer receiving intensity modulated radiotherapy and concurrent low-dose Cisplatin. Clin Lung Cancer 2013;14(5):541-8.
 
726 - Uyterlinde W (2013)
Uyterlinde W, Chen C, Kwint M, et al. Prognostic parameters for acute esophagus toxicity in intensity modulated radiotherapy and concurrent chemotherapy for locally advanced non-small cell lung cancer. Radiother Oncol. 2013;107(3):392-7.
 
727 - Vansteenkiste J (2013)
Vansteenkiste J, De Ruysscher D, Eberhardt W, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24 Suppl 6:vi89-98.
 
728 - Verstegen N (2011)
Verstegen N, Lagerwaard F, Haasbeek C, et al. Outcomes of stereotactic ablative radiotherapy following a clinical diagnosis of stage I NSCLC: comparison with a contemporaneous cohort with pathologically proven disease. Radiother Oncol 2011;101(2):250-254.
 
729 - Verstegen NE (2013)
Verstegen NE, Oosterhuis JW, Palma DA, et al. Stage I-II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched analysis. Ann Oncol 2013;24(6):1543-1548.
 
730 - Videtic G (2013)
Videtic G, Reddy C, Sorenson L. A prospective study of quality of life including fatigue and pulmonary function after stereotactic body radiotherapy for medically inoperable early-stage lung cancer. Support Care Cancer 2013;21(1):211-218.
 
731 - Wang L (2012)
Wang L, Wu S, Ou G, et al. Randomized phase II study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III non-small cell lung cancer. Lung Cancer 2012;77(1):89-96.
 
732 - Widder J (2013)
Widder J, Klinkenberg TJ, Ubbels JF, et al. Pulmonary oligometastases: metastasectomy or stereotactic ablative radiotherapy? Radiother Oncol 2013;107(3);409-413.
 
733 - Widder J (2011)
Widder J, Postmus D, Ubbels J, et al. Survival and quality of life after stereotactic or 3D-conformal radiotherapy for inoperable early-stage lung cancer. Int J Radiat Oncol Biol Phys 2011;81(4):e291-7.
 
734 - Woody NM
Woody NM, Videtic GM, Stephans KL, et al. Predicting chest wall pain from lung stereotactic body radiotherapy for different fractionation schemes. Int J Radiat Oncol Biol Phys;83(1):427-434.
 
735 - Yamaguchi S (2013)
Yamaguchi S, Ohguri T, Ide S, et al. Stereotactic body radiotherapy for lung tumors in patients with subclinical interstitial lung disease: The potential risk of extensive radiation pneumonitis. Lung Cancer 2013;82(2):260-265.
 
736 - Yq H (2014)
Yq H, Gong HL, Deng YF, Li WM. Diagnostic efficacy of PET and PET/CT for recurrent lung cancer: a meta-analysis. Acta Radiol 2014;55(3):309-317.
 
737 - Arcila ME (2012)
Arcila ME, Chaft JE, Nafa K, et al. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res 2012; 18(18): 4910-4918.
 
738 - Awad MM (2013)
Awad MM, Katayama R, McTigue M, et al. Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med 2013; 368(25): 2395–2401.
 
739 - Beelen R (2014)
Beelen R, Stafoggia M, Raaschou-Nielsen O, et al. Long-term exposure to air pollution and cardiovascular mortality: an analysis of 22 European cohorts. Epidemiology 2014; 25(3): 368-378.
 
740 - Bergethon K (2012)
Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012; 30(8): 863-870.
 
742 - Bishop JA (2012)
Bishop JA, Teruya-Feldstein J, Westra WH, et al. p40 (DeltaNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol 2012; 25: 405-415.
 
743 - Buttitta F (2006)
Buttitta F, Barassi F, Fresu G, et al. Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features. Int J Cancer 2006; 119(11): 2586–2591.
 
744 - Camidge DR (2012)
Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012; 13(10): 1011-1019.
 
745 - Cardarella S (2013)
Cardarella S, Ogino A, Nishino M, et al. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res 2013; 19(16): 4532–4540.
 
746 - Christensen JG (2007)
Christensen JG, Zou HY, Arango ME, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 2007 (12 Pt 1); 6: 3314-3322.
 
747 - Ciuleanu T (2012)
Ciuleanu T, Stelmakh L, Cicenas S, et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncology 2012; 13(3): 300-308.
 
748 - Collins LG (2007)
Collins LG, Haines C, Perkel R, Enck RE. Lung cancer: diagnosis and management. Am Fam Physician 2007; 75(1): 56-63.
 
749 - Douillard JY (2014)
Douillard JY, Ostoros G, Cobo M, et al. Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol 2014; 9(9): 1345-1353.
 
750 - Drift MA van der (2012)
Drift MA van der, Karim-Kos HE, Siesling S, et al. Progress in standard of care therapy and modest survival benefits in the treatment of non-small cell lung cancer patients in the Netherlands in the last 20 years. J Thorac Oncol 2012; 7(2): 291-298.
 
751 - Drilon A (2013)
Drilon A, Wang LL, Hasanovic A, et al. Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov 2013; 3(6): 630-635.
 
752 - Ettinger DS (2012)
Ettinger DS, Akerley W, Borghaei H, et al. Non-small cell lung cancer. J Natl Compr Canc Netw 2012; 10(10): 1236-1271.
 
753 - Garassino MC (2013)
Garassino MC, Martelli O, Broggini M, et al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncology 2013; 14(10): 981-988.
 
754 - Gautschi O (2012)
Gautschi O, Pauli C, Strobel K, et al. A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib. J Thorac Oncol 2012; 7(10): 23–24.
 
755 - Gridelli C (2012)
Gridelli C, Ciardiello F, Gallo C, et al. First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. J Clin Oncol 2012; 30(24): 3002-3011.
 
756 - Hirsh V (2013)
Hirsh V, Blackhall FH, Kim DW, et al. Impact of crizotinib on patient-reported symptoms and quality of life (QOL) compared with single-agent chemotherapy in a phase III study of advanced ALK+ non-small cell lung cancer (NSCLC). J Clin Oncol 2013; 31 (suppl; abstr 8108).
 
757 - Horeweg N (2014)
Horeweg N, Rosmalen, J van, Heuvelmans MA, et al. Lung cancer probability in patients with CT-detected pulmonary nodules: a prespecified analysis of data from the NELSON trial of low-dose CT screening. Lancet Oncol 2014; 15(12): 1332-1341.
 
758 - Janssen-Heijnen ML (1989)
Janssen-Heijnen ML, Karim-Kos HE, van der Drift MA, et al. Modest improvements of survival for patients with small cell lung cancer aged 45 to 59 years only, diagnosed in the Netherlands, 1989 to 2008. J Thorac Oncol 2012; 7(1): 227-232.
 
759 - Karampeazis A (2013)
Karampeazis A, Voutsina A, Souglakos J, et al. Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study. Cancer 2013; 119(15): 2754-2764.
 
760 - Kim DW (2012)
Kim DW, Ahn MJ, Shi Y, et al. Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol 2012; 30 (suppl; abstract 7533).
 
761 - Klaveren RJ van (2009)
Klaveren RJ van, Oudkerk M, Prokop M, et al. Management of lung nodules detected by volume CT scanning. N Engl J Med 2009; 361(23): 2221-2229.
 
762 - Kohno T (2012)
Kohno T, Ichikawa H, Totoki Y, et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med 2012; 18(3): 375–377.
 
763 - Kwak EL (2010)
Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363(18): 1693-1703.
 
764 - Lee CK (2013)
Lee CK, Brown C, Gralla RJ, et al. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst 2013; 105(9): 595-605.
 
765 - Lee SM (2012)
Lee SM, Khan I, Upadhyay S, et al. First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology 2012; 13(11): 1161-1170.
 
766 - Lindeman NI (2013)
Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med. 2013 Jun;137(6):828-60.
 
767 - Mazières J (2013)
Mazières J, Peters S, Lepage B, et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol 2013; 31(16): 1997–2003.
 
768 - Miller VA (2012)
Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung1): a phase 2b/3 randomised trial. Lancet Oncology 2012; 13(5): 528-538.
 
769 - Molina JR (2008)
Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008; 83(5): 584-594.
 
770 - Mukhopadhyay S (2011)
Mukhopadhyay S, Katzenstein AL. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6. Am J Surg Pathol 2011; 35: 15–25.
 
771 - National Lung, Aberle DR (2011)
National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365(5): 395-409.
 
772 - National Lung, Church TR (2013)
National Lung Screening Trial Research Team, Church TR, Black WC, et al. Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med 2013; 368(21): 1980-1991.
 
773 - Nonaka D (2012)
Nonaka D. A study of DeltaNp63 expression in lung non-small cell carcinomas. Am J Surg Pathol 2012; 36: 895-899.
 
774 - Ou SH (2014)
Ou SH, Jänne PA, Bartlett CH, et al. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. Ann Oncol 2014; 25(2): 415-422.
 
775 - Pelosi G (2012)
Pelosi G, Fabbri A, Bianchi F, et al. DeltaNp63 (p40) and thyroid transcription factor-1 immunoreactivity on small biopsies or cellblocks for typing non-small cell lung cancer: a novel two-hit, sparing-material approach. J Thorac Oncol 2012; 7: 281-290.
 
776 - Pelosi G (2011)
Pelosi G, Rossi G, Bianchi F, et al. Immunhistochemistry by means of widely agreed-upon markers (cytokeratins 5/6 and 7, p63, thyroid transcription factor-1, and vimentin) on small biopsies of non-small cell lung cancer effectively parallels the corresponding profiling and eventual diagnoses on surgical specimens. J Thorac Oncol 2011; 6: 1039-1049.
 
777 - Peters S (2012)
Peters S, Adjei AA, Gridelli C, et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23(Suppl 7): vii56-vii64.
 
778 - Peters S (2013)
Peters S, Michielin O, Zimmermann S. Dramatic Response Induced by Vemurafenib in a BRAF V600E-Mutated. J Clin Oncol 2013;31(20):341–4.
 
779 - Pleasance ED (2010)
Pleasance ED, Stephens PJ, O’Meara S, et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 2010; 463(7278): 184-190.
 
780 - Raaschou-Nielsen O (2013)
Raaschou-Nielsen O, Andersen ZJ, Beelen R, et al. Air pollution and lung cancer incidence in 17 European cohorts: prospective analyses from the European Study of Cohorts for Air Pollution Effects (ESCAPE). Lancet Oncol 2013; 14(9): 813-822.
 
781 - Rikova K (2007)
Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007; 131(6): 1190-1203.
 
782 - Robinson SD (2014)
Robinson SD, O’Shaugnessy JA, Cowey CL, et l. BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib. Lung Cancer 2014; 85(2): 326-330.
 
783 - Rosell R (2012)
Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicenter, open-label, randomised phase 3 trial. Lancet Oncology 2012; 13(3): 239-246.
 
784 - Sequist LV (2013)
Sequist LV, Yang JCH, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013; 31(27): 3327-3334.
 
785 - Shaw AT (2014)
Shaw AT, Kim D-W, Mehra R, et al. Ceritinib in ALK-rearranged non–small-cell lung cancer. N Engl J Med 2014; 370: 1189-1197.
 
786 - Shaw AT (2013)
Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013; 368(25): 2385-2394.
 
787 - Shaw AT (2011)
Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011; 12(11): 1004-1012.
 
788 - Shigematsu H (2005)
Shigematsu H, Takahashi T, Nomura M, et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 2005; 65(5): 1642-1646.
 
789 - Soda M (2007)
Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448(7153): 561-566.
 
790 - Soda M (2008)
Soda M, Takada S, Takeuchi K, et al. A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci U S A 2008; 105(50): 19893-19897.
 
791 - Solomon BJ (2014)
Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014; 371(23): 2167-2177.
 
792 - Stephens P (2004)
Stephens P, Hunter C, Bignell G, et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 2004; 431(7008): 525-526.
 
793 - Suehara Y (2012)
Suehara Y, Arcila M, Wang L, et al. Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions. Clin Cancer Res 2012; 18(24): 6599-6608.
 
794 - Tacha D (2014)
Tacha D, Bremer R, Haas T, et al. An immunohistochemical analysis of a newly developed, mouse monoclonal p40 (BC28) in lung, bladder, skin, breast, prostate, and head and neck cancers. Arch Pathol Lab Med 2014; 138: 1358-1364.
 
795 - Thunnissen E (2012)
Thunnissen E, Boers E, Heideman DA, et al. Correlation of immunohistochemical staining p63 and TTF-1 with EGFR and K-ras mutational spectrum and diagnostic reproducibility in non small cell lung carcinoma. Virchows Arch 2012; 461: 629–38.
 
796 - Travis WD (2011)
Travis WD, Brambilla E, Noguchi M, et al. Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. Arch Pathol Lab Med 2013; 137(5): 668-684.
 
797 - Tsao MS (2013)
Tsao MS, Hirsch FR, Yatabe Y. IASLC Atlas of ALK testing in lung cancer. International Association for the Study of Lung Cancer. Aurora, Colorado, USA, 2013.
 
798 - Villanti AC (2013)
Villanti AC, Jiang Y, Abrams DB, Pyenson BS. A cost-utility analysis of lung cancer screening and the additional benefits of incorporating smoking cessation interventions. PLoS One 2013; 8(8): e71379, doi 10.1371/journal.pone.0071379.
 
799 - Wang R (2012)
Wang R, Hu H, Pan Y, et al. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol 2012; 30(35): 4352-4359.
 
800 - WHO (2009)
WHO, 2009
 
801 - Wu YL (2013)
Wu YL, Lee JS, Thongprasert S, et al. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. Lancet Oncology 2013; 14(8): 777-786.
 
802 - Wu YL (2014)
Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomized phase 3 trial. Lancet Oncology 2014; 15(2): 213-222.
 
803 - Yang JCH (2013)
Yang JCH, Hirsh V, Schuler M, et al. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013; 31(27): 3342-3350.
 
804 - Yoshida A (2013)
Yoshida A, Kohno T, Tsuta K, et al. ROS1-Rearranged Lung Cancer. A clinicopathologic and molecular study of 15 surgical cases. Am J Surg Pathol. 2013; 37(4): 554-562.
 
805 - Zou HY (2007)
Zou HY, Li Q, Lee JH, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007; 67(9): 4408-4417.
 
806 - Paz-Ares (2012)
Paz-Ares L, de Marinis F, Dediu M, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomized controlled trial. Lancet Oncology 2012; 13(3): 247-255.
 
807 - Pérol (2012)
Pérol M, Chouiad C, Pérol D, et al. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2012; 30(28): 3516-3524.
 
808 - Fairchild A (2008)
Fairchild A, Harris K, Barnes E, Wong R, Lutz S, Bezjak A, et al. Palliative thoracic radiotherapy for lung cancer: a systematic review. J Clin Oncol. 2008;26(24):4001-11.
 
809 - Lester JF (2006)
Lester JF, Macbeth FR, Toy E, Coles B. Palliative radiotherapy regimens for non-small cell lung cancer. Cochrane Database of Systematic Reviews. 2006;4(4):CD002143.
 
810 - Ma J-T (2014)
Ma J-T, Zheng J-H, Han C-B, Guo Q-Y. Meta-analysis comparing higher and lower dose radiotherapy for palliation in locally advanced lung cancer. Cancer Sci 2014;105(8):1015-22.
 
811 - Ma J-T (2015)
Ma J-T, Han C-B, Zheng J-H, Guo Q-Y. Response to “Letter to the Editor - A meta-analysis comparing higher and lower dose radiotherapy for palliation in locally advanced lung cancer”. Cancer Sci 2015;106(6):783.
 
812 - Reveiz L (2012)
Reveiz L, Rueda J-R, Cardona AF. Palliative endobronchial brachytherapy for non-small cell lung cancer. Cochrane Database of Systematic Reviews. 2012;12.
 
813 - Sau S (2014)
Sau S, Sau S, Dutta P, Gayen GC, Banerjee S, Basu A. A comparative study of different dose fractionations schedule of thoracic radiotherapy for pain palliation and health-related quality of life in metastatic NSCLC. Lung India. 2014;31(4):348-53.
 
814 - Ung Y.C (2006)
Ung Y.C, Yu E, Falkson C, Haynes A.E, Stys-Norman D, Evans W.K, et al. The role of high-dose-rate brachytherapy in the palliation of symptoms in patients with non-small-cell lung cancer: A systematic review. Brachytherapy. 2006;5(3):189-202.
 
815 - Vlayen J (2015)
Vlayen J, Belderbos J, Widder J. Letter to the Editor - Meta-analysis comparing higher and lower dose radiotherapy for palliation in locally advanced lung cancer. Cancer Sci 2015;106(6):782.